The Effect of Acute Docosahexaenoic Acid Intake on Left Ventricular Function and Susceptibility to Ischemia-Reperfusion Injury in the Isolated Rat Heart by Streit, Isaac
  
The Effect of Acute Docosahexaenoic Acid Intake on Left Ventricular Function and 
Susceptibility to Ischemia-Reperfusion Injury in the Isolated Rat Heart   
 
by 
 
Isaac Streit 
 
 
 
 
A thesis  
presented to the University of Waterloo 
in fulfillment of the  
thesis requirement for the degree of 
Master of Science  
in  
Kinesiology 
 
 
Waterloo, Ontario, Canada, 2015 
© Isaac Streit 2015
  
ii 
 
Author's Declaration 
I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, 
including any required final revisions, as accepted by my examiners.  
I understand that my thesis may be made electronically available to the public. 
  
iii 
 
Abstract 
The chronic intake and myocardial incorporation of n-3 highly unsaturated fatty acids 
(HUFA), particularly docosahexaenoic acid (22:6n-3, DHA), is believed to protect against 
ischemia-reperfusion injury, possibly through oxidative stress-dependent upregulation of 
enzymatic antioxidants.  These adaptations may occur as early as 24 hours after the initial intake, 
but the effect of acute (<24 hour) DHA intake on myocardial DHA accretion, susceptibility to 
ischemia-reperfusion injury, and content of enzymatic antioxidants has not been characterized.  
Additionally, recent research suggests that acute intake patterns may be the norm in human 
populations, and thus it is important to study the effect of this dietary pattern on cardiovascular 
physiology.  Therefore, Sprague-Dawley and Wistar rats were exposed to a one time gavage of a 
high DHA oil (DHASCO, 0.4 mg DHA/g body weight) to study the effect of acute DHA intake 
on left ventricular function and susceptibility to ischemia-reperfusion in the Langendorff ex vivo 
rat isolated heart model.  Left ventricular myocardial samples were collected and analysed for 
total fatty acids, neutral lipid composition by thin layer chromatography, lipidomics by HPLC 
MS-MS, and the enzymatic antioxidants MnSOD, CuZnSOD, and GPx by western blotting.  A 
single dose of DHA affects the fatty acid profiles of both plasma and left ventricle at 24 hours.  
The concentration of both eicosapentaenoic acid (EPA) and DHA is increased in plasma total 
lipids, with a corresponding decrease in the relative percent of the n-6 HUFA arachidonic acid 
(ARA) and adrenic acid (p<0.05).  EPA is additionally elevated in the total lipids of the left 
ventricle (p<0.05), with a non-significant trend towards increased DHA (p=0.053).  However, 
left ventricular phospholipid and triacylglycerol DHA concentrations are significantly elevated 
24 hours following DHA treatment (p<0.05).  Lipidomic analysis demonstrated a trend towards 
increasing total DHA (p=0.081) and DHA in phosphatidylethanolamine (PE, p=0.078) fractions, 
  
iv 
 
primarily driven by increases in 16:0/DHA PE, although this did not reach statistical 
significance.  This altered lipid profile is associated with reduced baseline left ventricular 
function in Sprague-Dawley male rats (p<0.05), but improved post-ischemic left ventricular 
functional recovery (p<0.05) and reduced infarction (p<0.05 when males and females were 
combined) in a constant flow isolated heart model.  An effect of DHA treatment on left 
ventricular function was not observed in Sprague-Dawley female rats (p>0.05).  DHA-fed male 
Wistar rats perfused with constant pressure had higher coronary flow during reperfusion 
(p<0.05), but DHA treatment in these animals did not reduce infarction (p>0.05), indicating that 
the effect of acute DHA treatment on ischemia-reperfusion injury is dependent on animal strain 
and the method of heart perfusion.  There was no effect of acute DHA feeding on the myocardial 
protein content of the enzymatic antioxidants CuZnSOD, MnSOD, and GPx (p>0.05).  
Therefore, a single dose of DHA increases plasma and myocardial EPA and DHA content at 24 
hours and affects myocardial and vascular function at 24 hours dependent on strain and sex.  
This effect is independent of increases in the myocardial protein content of the enzymatic 
antioxidants tested. 
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Chapter 1 
Introduction 
 
The n-3 highly unsaturated fatty acids (HUFA, ≥20 carbons, ≥3 carbon-carbon double bonds) 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been studied extensively in 
relation to their benefit to cardiovascular health (Mozaffarian & Wu 2011).  Increased dietary 
intake (Burr et al., 1989; GISSI, 1999) and elevated blood levels (Albert et al. 2002) of n-3 
HUFA are associated with reduced cardiovascular disease mortality in humans, but recent meta-
analyses of clinical interventions have indicated that prescribing an increased intake of n-3 
HUFA may not reduce cardiovascular events (Kwak et al. 2012; Rizos et al. 2012), casting doubt 
on their clinical efficacy.  Although cardioprotective effects of n-3 HUFA have been observed in 
myocardial cell culture (Xiao et al. 1997), ex vivo (Zeghichi-Hamri et al. 2010), and in vivo 
(McLennan et al. 1993) animal models, the understanding of the effect of n-3 HUFA on 
molecular and physiological pathways of the cardiovascular system, including the heart, is 
incomplete (Mozaffarian & Wu 2011).  It is therefore essential to further the mechanistic 
understanding of the role n-3 HUFA in order to increase their clinical utility in the prevention 
and treatment of cardiovascular disease.    
The role of n-3 HUFA in cardiovascular disease is complicated by the fact that they affect the 
heart through numerous mechanisms (Mozaffarian & Wu 2011).  This includes  modulation of 
myocardial ion channels (Xiao et al. 2001), changes in the profiles of bioactive lipid mediators 
(Kelley et al. 1999), and through their structural role in plasma and mitochondrial lipid 
membrane biophysics (Gawrisch et al. 2003).    These mechanisms may, individually or in sum, 
contribute to observed reductions in arrhythmias (McLennan et al. 1985), infarction (Castillo et 
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al. 2013; Zeghichi-Hamri et al. 2010) and increases in post-ischemic blood flow (Force et al. 
1989) that are associated with n-3 HUFA treatment in animal models.  However, n-3 HUFA also 
increase the oxidative stress that the myocardium is subjected to (Castillo et al. 2013), both 
through their generation of reactive oxygen species (ROS) (Aires et al. 2007) and their 
susceptibility to lipid peroxidation (Saito & Kubo 2003).  Although ROS contribute to ischemia-
reperfusion injury (Kim et al. 2006; Temsah et al. 1999), they also serve as a stimulus to increase 
the hearts resistance to future oxidative stress through a phenomenon known as preconditioning 
(Bolli 2000).  Late phase preconditioning protects the myocardium from ischemia-reperfusion 
injury from 24-72 hours after the preconditioning stimulus, and depends on the de novo synthesis 
of protective proteins, including enzymatic antioxidants (Bolli 2000).  Recent studies 
(Abdukeyum et al. 2008; McGuinness et al. 2006), as well as investigations in our lab (Smith et 
al. 2012), have suggested that n-3 HUFA may act  like preconditioning agents, possibly through 
oxidative stress pathways.  In support of this, chronic dietary intervention with n-3 HUFA has 
been shown to increase cellular antioxidant enzymes (Jahangiri et al. 2006) and, importantly, to 
afford protection from ischemia-reperfusion injury (Castillo et al. 2013).  However, currently no 
information exists regarding the potential of acute n-3 HUFA intake to effect adaptions in left 
ventricular function and ischemic susceptibility in the late phase window (24-72 hours) of 
preconditioning.  This is particularly relevant given the acute intake patterns observed in humans 
(Patterson et al. 2014), and may help to explain the discordance between positive laboratory 
findings and their translation to cardioprotection in clinical populations.  Important sex 
differences in n-3 HUFA metabolism (Kitson et al. 2012) and susceptibility to ischemia-
reperfusion injury (Bae & Zhang 2005) also exist which may influence the cardiovascular effects 
of acute n-3 HUFA intake and should therefore be characterized.   
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  This thesis therefore aims to investigate the effect of acute DHA intake on the left 
ventricular function and ischemic susceptibility of the isolated rat heart 24 hours after a single 
DHA feeding.  It was necessary to complete preliminary method development, which included 
examining a time course for ischemia prior to reperfusion and sex differences in response to 
DHA exposure, and considerations in regard to rat strain and isolated heart perfusion protocols, 
as these factors affect the myocardial response to ischemia-reperfusion injury.  The DHA 
treatment involved oral gavage and was compared with a soybean oil control.  In addition to left 
ventricular function and heart infarction, levels of DHA in plasma and left ventricle, as well as 
the protein content of enzymatic antioxidants, were measured.   
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Chapter 2 
Biochemical and Physiological Foundations 
 
Understanding the effect of acute DHA intake on ischemia-reperfusion injury in the isolated 
heart requires insight into not only DHA absorption and metabolism, but also understanding of 
the processes of both cardiac function and ischemia-reperfusion injury and the models used in 
their study, with particular focus on the Langendorff.  Recent evidence has suggested the 
potential of DHA to impact the heart through induction of oxidative stress, alteration of lipid 
mediator signalling, and modulation of cell membrane structure and function.  Importantly, the 
form of DHA, the feeding protocols (i.e. acute vs. chronic dietary interventions), and the sex of 
animals tested have important implications for the effects on cardiovascular function and 
susceptibility to ischemia-reperfusion injury and, therefore, must also be considered. 
 
2.1. The Langendorff Isolated Heart 
A common model used to study cardiovascular physiology is the Langendorff isolated heart.  
Developed in 1895 by Oscar Langendorff, the isolated heart has facilitated the discovery of 
numerous aspects of cardiovascular physiology, and in modified forms it continues to be used to 
this day.  This well-established model has the advantage that, in isolating the heart, it eliminates 
the potentially confounding influences of neural and hormonal factors, making it ideal for the 
mechanistic study of the myocardium (Skrzypiec-Spring et al. 2006).    
In the Langendorff preparation, the heart is excised, cannulated via the ascending aorta, and 
perfused in retrograde.  The perfusion solution enters the coronary arteries via the ostia, and, 
following the perfusion of the myocardium, exits via the coronary sinus and right atria (Bell et al. 
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2011).  With this supply of oxygen and metabolic substrates, the heart is able to maintain 
contractile function for several hours. Several perfusion solutions have been employed in the 
Langendorff model, including donor blood from another animal, buffers supplemented with 
isolated red blood cells, and bicarbonate-buffer based physiological solutions, although the latter 
is the most common in the literature.   
The supply of perfusion solution to the Langendorff isolated heart can be maintained with 
either constant pressure or constant flow, and the method used impacts heart function.  In 
constant flow perfusion, a peristaltic pump is used to deliver a constant amount of perfusion 
solution based on the estimated coronary flow of the experimental animal (Bell et al. 2011).  
Using this method has the advantage of delivering a known, constant volume of perfusion 
solution to the heart.  However, with constant flow the coronary vasculature is unable to regulate 
flow as it does in vivo.  Conversely, in constant pressure perfusion the hydrostatic pressure of the 
perfusion solution is kept constant, allowing the coronary vasculature to control the flow rate.  
For this reason, constant pressure perfusion is considered to be more physiologically relevant 
(Skrzypiec-Spring et al. 2006).   
 
2.2. Myocardial Ischemia-Reperfusion Injury 
Ischemia is the absence of blood flow to a tissue which results in reduced oxygen supply, 
substrate delivery, and metabolite removal (Murphy & Steenbergen 2008).  Reperfusion, or the 
restoration of blood flow to ischemic tissue, is required in order to salvage myocardial cells, but, 
counterintuitively, is also itself an injurious process (Hoffman et al. 2004).  Ischemia-reperfusion 
injury adversely affects the force generation (Bolli & Marbán 1999) and relaxation (Piper et al. 
2003) of the myocardium, due in part to impairment of myocardial Ca
2+
 sensitivity (Van Eyk et 
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al. 1998; Gao et al. 2014) and SERCA function (Temsah et al. 1999).  Additionally, myofilament 
contracture, defined as sustained shortening of the myocardium,  reduces myocardial relaxation 
(Piper et al. 2003) and increases cardiomyocyte susceptibility to mechanical damage (Schlüter et 
al. 1996).  Significant portions of the myocardium may also be lost to infarction, which is caused 
by apoptotic and necrotic cell death (Kalogeris et al. 2012), as well as autophagy (Hamacher-
Brady et al. 2006). 
There are a number of metabolic changes that occur during myocardial ischemia-reperfusion 
which contribute to the observed functional impairment and infarction.  Oxidative metabolism is 
arrested in the ischemic myocardium, resulting in the depletion of cellular high-energy 
phosphates, with levels of creatine phosphate falling more rapidly that ATP (Murphy & 
Steenbergen 2008).  With increased anaerobic glycolysis, as well ATP breakdown (Smith et al. 
1993), cellular pH also drops rapidly in the ischemic heart (Murphy et al. 1991).  Depletion of 
ATP affects the functioning of ATP-dependent enzymes and ion channels, resulting in increased 
levels of cytosolic Na
+
 (Malloy et al. 1990; Pike et al. 1990) and Ca
2+
 (Steenbergen et al. 1987; 
Imahashi et al. 2005).   
Furthermore, ischemia-reperfusion injury results in increases in myocardial oxidative stress, 
which has been implicated as a major contributor to the myocardial functional impairment and 
damage observed (Kim et al. 2006; Temsah et al. 1999).  ROS are highly reactive molecules and 
atoms containing oxygen, which have the potential to abstract protons from lipids, proteins, and 
DNA resulting in cellular damage (Freeman & Crapo 1982).  ROS are produced by the 
myocardium both during ischemia (Becker et al. 1999) and reperfusion (Kevin et al. 2003), 
although the amount of ROS produced during reperfusion is greater.  The primary sources of 
superoxide (O2
-
), the predominant ROS produced early in ischemia-reperfusion, are electron 
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transport chain enzymes, including cytochrome p450 oxidases, and oxidation enzymes such as 
xanthine oxidase (Kalogeris et al. 2012; Zweier & Talukder 2006).  If they are not neutralised by 
the cell’s innate oxidative stress handling systems, ROS in the myocardium are pro-arrhythmic 
(Opie 1989), alter intracellular Ca
2+
 levels (Aires et al. 2007), induce inflammatory responses 
(Rodrigo et al. 2013), and cause the mitochondrial permeability transition pore to open 
(Halestrap et al. 2004), resulting in apoptotic and necrotic cell death (Gottlieb et al. 1994; Reeve 
et al. 2007). 
 
2.3. Cardiac Excitation-Contraction Coupling 
Cardiac excitation-contraction coupling is defined as the series of physiological processes 
occurring from electrical excitation of the cardiomyocyte to Ca
2+
-induced contraction of the 
myofilaments (Bers 2002).  L-type Ca
2+
 channels, located at the sarcolemmal-sarcoplasmic 
reticulum (SR) junction, open in response to an action potential resulting in Ca
2+ 
influx 
(Meissner & Lu 1995).  This in turn activates SR Ca
2+
 release through ryanodine receptors (RyR) 
resulting in an increase in cytosolic Ca
2+
 concentrations (Meissner & Lu 1995).  Cytosolic Ca
2+
 
binds to the myofilament regulatory protein troponic C, causing dissociation of tropomyosin 
from the actin filaments (Gordon et al. 2000).  This reaction frees the myosin binding sites on the 
actin molecule allowing cross bridge cycling, and a myofilament contraction, to occur (Gordon 
et al. 2000).  The force of the cardiac contraction (contractility) is dependent on both the 
cytosolic Ca
2+
 concentration and the sensitivity of the myofilaments to the Ca
2+ 
signal (Bers 
2002). 
Relaxation of the myocardium requires that Ca
2+
 dissociate from troponin C, thus allowing 
tropomyosin to occupy its position on the actin molecule blocking myosin binding sites and cross 
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bridge cycling (Bers 2002).  For relaxation to occur, Ca
2+
 concentrations in the cytosol must be 
reduced by the concerted action of several transport proteins including the sarcoplasmic-
endoplasmic reticulum Ca
2+ 
ATPase (SERCA), Na
+
/ Ca
2+
 exchanger (NCX), plasmalemmal Ca
2+ 
ATPase (PMCA), and the mitochondrial Ca
2+
 uniporter (Bers 2002).  The latter 2 proteins are 
referred to collectively as the slow systems, and contribute minimally to Ca
2+
 removal (Bassani 
et al. 1994).  In rats, SERCA handles the majority (~92%) of Ca
2+
 removal, with the balance of 
Ca
2+
 removal proceeding through forward action of NCX (~7%) and slow systems (~1%) 
(Bassani et al. 1994). 
The Langendorff isolated heart can be instrumented in order to measure the effect of 
ischemia-reperfusion injury on cardiac excitation-contraction coupling.  Systolic pressure is the 
peak of the left ventricular pressure waveform and describes the highest amount of force that the 
myocardium develops within a given beat.  Diastolic is used to measure contracture, an indicator 
of ischemia-reperfusion injury caused by myocardial ionic disturbances.  Contractility, or 
developed pressure, is the difference between systolic and diastolic pressure and is an indicator 
of the heart’s ability to generate force.  Contractility is dependent on both the Ca2+ levels in the 
cytosol, and the sensitivity of the myofilaments to Ca
2+
.  The rates of contraction and relaxation 
are derivatives of the left ventricular pressure waveform.  Rate of contraction is dependent on 
excitation-contraction coupling and myofilament Ca
2+
 sensitivity.  The rate of relaxation is 
primarily determined by the activity of SERCA in sequestering Ca
2+
 in the SR.  The responses of 
these variables to the nutritional intervention and ischemia-reperfusion protocol provide insight 
into the specific physiological changes occurring in the myocardium.  
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2.4. Effects of N-3 HUFA on Cardioprotection 
The n-3 HUFA EPA and DHA affect numerous biological pathways and systems, which 
complicates the understanding of their mechanistic role in cardiovascular disease.  Although 
EPA and DHA are traditionally found together in dietary sources, and have often been studied in 
combination, they may have differential effects on the cardiovascular system (Cottin et al. 2011). 
Following dietary intake, EPA and DHA are differentially incorporated into the plasma (Hodge 
et al. 1993) and tissues (Frøyland et al. 1996).  Additionally, supplementation with DHA, but not 
EPA, affects hemodynamics and heart rate in humans (Mori et al. 1999).  As compared with 
EPA, DHA is more susceptible to peroxidation (Saito & Kubo 2003), indicating that it may 
increase oxidative stress to a greater extent than EPA.  Therefore, EPA and DHA should be 
studied independently in order to gain a complete understanding of their mechanistic effects.     
Chronic dietary supplementation with EPA + DHA has been found to increase myocardial 
resistance to ischemia-reperfusion injury (Castillo et al. 2013; Zeghichi-Hamri et al. 2010; 
Abdukeyum et al. 2008) and to improve post-ischemic blood flow (Force et al. 1989).  These 
studies employ high dose gavage or modified chow diets to effect increases in myocardial 
phospholipid n-3 HUFA, while simultaneously displacing the predominant n-6 HUFA 
arachidonic acid (ARA, C 20:4n-6).  Although the altered myocardial fatty acid profile appears 
to be cardioprotective in ischemia-reperfusion injury, the specific mechanisms involved have not 
been fully elucidated.  Increased n-3 HUFA in myocardial phospholipids following chronic 
dietary intervention may affect several parameters and pathways relevant to ischemia-reperfusion 
injury including membrane structure and function, fatty acid-derived eicosanoids, and oxidative 
stress pathways (discussed in detail in sections 2.5, 2.6, and 2.7 respectively).       
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There is also evidence for cardioprotective effects of free n-3 HUFA administered acutely 
during an ischemia-reperfusion protocol, indicating that n-3 HUFA can act independently of 
their incorporation into myocardial phospholipids.  Acute infusions of DHA immediately 
following an ischemic stress result in reductions in infarction (Smith et al. 2012); acute n-3 
HUFA treatment has also been shown to reduce arrhythmias in isolated rat cardiomyocytes 
(Kang & Leaf 1994) and in vivo animal models (McLennan et al. 1993).  As n-3 HUFA are not 
incorporated into the myocardial membrane phospholipids in these experiments, these results are 
independent of phospholipid composition, and thus reflect an acute effect of free n-3 HUFA.  
These near immediate effects on the heart primarily involve ion channel interactions, which are 
hypothesized to result in the observed anti-arrhythmic effects (Billman et al. 1997).  N-3 HUFA 
interact directly with myocardial ion channels including the voltage gated L-type Ca
2+
 channel 
(Xiao et al. 1997) and the alpha subunit of the sodium channel (Xiao et al. 2001), which may 
contribute to observed reductions in myocardial excitability with acute n-3 HUFA treatment 
(Kang et al. 1995).  It is likely a combination of the acute and chronic effects of n-3 HUFA that 
contributes to observed reductions in cardiovascular disease, although determining their 
individual mechanistic contributions, both in laboratory and clinical settings, has proven 
difficult.      
 
2.5. Effects on Membrane Structure and Function 
N-3 HUFA are found primarily in the sn-2 position of plasma membrane phospholipids.  
However, de novo phospholipid synthesis through the Kennedy pathway (Kennedy & Weiss 
1956) results in phospholipids rich in monounsaturated and diunsaturated fatty acids in the sn-2 
position, with little n-3 HUFA present.  Instead, n-3 HUFA are incorporated into the plasma 
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membrane phospholipids through a remodelling process known as the Lands cycle (Lands 1958).  
Through a series of deacylation and reacylation reactions, the fatty acids esterified to the sn-2 
position of individual phospholipids are altered from their de novo composition.   
Due to the unique chemical structure and 3-dimensional configuration of DHA, its 
incorporation into phospholipids of plasma or organelle membranes alters their structure and 
function.  Incorporation of DHA alters the biophysical properties of the membrane resulting in 
increases in membrane fluidity, ion permeability, lipid raft dynamics, and fusion (reviewed in 
Stillwell & Wassall, 2003).   These biophysical changes, along with direct interaction of DHA 
with ion channels and transmembrane proteins, affect numerous biological processes carried out 
at the membrane (Lee et al. 2003; Wong et al. 2009).   
Incorporation of EPA and DHA also affects the ion permeability and electrochemical 
gradient of the plasma membrane though modulation of ion channel kinetics.  The n-3 HUFA 
affect lipid raft dynamics as previously discussed, and the ion channels that localize in these 
membrane microdomains are modulated by the specific lipid raft structure (reviewed in Dart, 
2010).  It is important to note, however, that most ion channel interactions are caused by free n-3 
HUFA (discussed in section 2.4).  During ischemia, the activity of plasmalogen-specific 
phospholipase A2 is increased (Ford et al. 1991), resulting in cleavage of fatty acyls including n-
3 HUFA from the sn-2 position of plasma membrane phospholipids.  This pool of liberated n-3 
HUFA could potentially exert anti-arrhythmic effects through the known interactions with ion 
channels demonstrated in acute cultured cardiomyocyte studies. 
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2.6. Lipid Mediators of Inflammation 
The pathogenesis of cardiovascular disease is characterized by increased inflammation (Kain 
et al. 2014), and one of the pathways through which DHA is thought to ameliorate 
cardiovascular disease is through its role as a precursor to lipid mediator signalling molecules 
which have anti-inflammatory properties. The n-3 derived docosanoids have recently been 
identified as important mediators of inflammation resolution, controlling both the duration and 
magnitude of the inflammatory response (reviewed in Serhan, 2007).  This class of pro-
resolution compounds, termed specialized pro-resolving mediators, includes both resolvins and 
protectins.  DHA is a precursor to protectins and D series resolvins.  These compounds act to 
resolve inflammation through reduction of polymorphonuclear leukocyte migration and 
infiltration, cytokine production, and ROS generation (Serhan et al., 2000).    
Lipid mediators can also be derived from the dominant n-6 HUFA ARA.  When cleaved 
from membrane phospholipids by phospholipase A2, ARA serves as a substrate for eicosanoid 
synthesis via enzymatic oxidation by cyclooxygenase, lipoxygenase, and cytochrome P450.  
Some of the eicosanoids derived from the predominant n-6 HUFA ARA, including leukotriene-
B4 and thromboxane-A2, are pro-inflammatory and are thus considered to be detrimental to 
cardiovascular health (Mozaffarian & Wu 2011).  DHA can compete in eicosanoid synthesis 
pathways by both displacing ARA in the membrane and directly inhibiting n-6 series eicosanoid 
synthesis, resulting in an overall decrease in production of these pro-inflammatory eicosanoids 
(Kelley et al. 1999).   
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2.7. N-3 HUFA and Oxidative stress 
Lipid peroxidation is the redox process through which protons are abstracted from lipids by 
ROS, resulting in lipid radical products.  These products are dangerously reactive and can 
damage cellular components and increase intracellular oxidative stress (Halliwell & Chirico 
1993).  The susceptibility of n-3 PUFA to lipid peroxidation is correlated with the number of 
double bonds in membrane phospholipids (Saito & Kubo 2003); therefore, a highly unsaturated 
fatty acid such as DHA may increase ROS-induced lipid peroxidation.    
Chronic dietary intervention with n-3 HUFA has been correlated with increases in oxidative 
stress in several systems studied including isolated endothelial cells (Vossen et al. 1995), rat 
plasma (Song et al. 2000), liver cells (Farina et al. 2003), mouse kidney (Ibrahim et al. 1999), 
and human blood (Garcia-Alonso et al. 2012).  The treatment with n-3 HUFA need not be 
chronic in order to elicit increases in tissue oxidative stress, as supply of high concentrations of 
n-3 HUFA has been shown to induce rapid ROS generation (Feng et al. 2012).   
Although this oxidative challenge can induce apoptosis through ROS-mediated activation of 
the intrinsic apoptotic pathway (Diep et al. 2000; Aires et al. 2007), it may also serve to signal 
the myocardium to increase its oxidative stress handling capacity through increasing enzymatic 
antioxidants.  One pathway involved may be the signalling of the n-3 derived lipid peroxidation 
product, 4-hydroxyhexenal (4-HXE) which upregulates enzymatic antioxidants (Nakagawa et al. 
2014) through the transcription factor Nrf2 (Ishikado et al. 2013).  Chronic n-3 HUFA feeding 
increases both 4-hydroxyhexenal levels (Anderson et al. 2012) and antioxidant enzymes in the 
murine heart (Anderson et al. 2012; Jahangiri et al. 2006; Castillo et al. 2013), and results in 
improved recovery following ischemia-reperfusion injury in isolated hearts (Castillo et al. 2013).  
Therefore, myocardial membrane incorporation of n-3 HUFA may induce ROS and reactive 
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aldehyde production below the level required for activation of the intrinsic apoptotic pathway, 
which may instead serve as a stimulus for upregulation of enzymatic antioxidants.  However, no 
studies have tested the ability of n-3 HUFA to effect similar adaptions in the left ventricular 
function and ischemic susceptibility in an acute (<24 hour) time frame.   
 
2.8. Role of ROS and Oxidative Stress in IR 
Myocardial functional impairment and damage following ischemia-reperfusion injury is 
caused in large part by ROS (Kim et al. 2006; Temsah et al. 1999), and thus these molecules are 
a target for potential cardioprotective interventions.  Increasing the heart’s antioxidant defences 
through the addition of exogenous antioxidant defence enzymes has been shown to reduce 
infarction in some (Adlam et al. 2005; Bognar et al. 2006; Jones et al. 2003), but not all studies 
(Gallagher et al. 1986; Ooiwa et al. 1991; Vanhaecke et al. 1991), possibly due to differences in 
the specificity and cellular localisation of antioxidants used (Sheu et al. 2006).  Therefore, the 
administration of exogenous antioxidants may not be a viable method for cardioprotection.  
However, increasing the endogenous antioxidant defences of the myocardium through a method 
known as preconditioning may be an alternative. 
Preconditioning is defined as a stressor that elicits an adaptive response which attenuates 
damage from future stressors.  An example occurs in the myocardium when it is exposed to brief 
periods of ischemia, as the heart adapts to become more resistant to future ischemic insults.  
Since the initial investigations by Murry et al. (Murry et al. 1986), this phenomenon, known as 
ischemic preconditioning, has shown promise in its ability to reduce many aspects of ischemia-
reperfusion injury, including a reduction in apoptotic and necrotic cell death, reperfusion 
arrhythmias, and myocardial stunning (Pagliaro et al. 2001).  Traditional ischemic 
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preconditioning employs short (<5 minute) bouts of ischemia before the main ischemic insult to 
induce cardio-protection (Penna et al. 2009), although other preconditioning stimuli elicit a 
similar cardioprotective effect, including exercise-induced (Chicco et al. 2007), heat stress 
(Yamashita et al. 1998), and pharmacological (Forbes et al. 2001) preconditioning.  This 
myocardial preconditioning effect is ubiquitous in the animal kingdom, and has been 
demonstrated in all species studied (Nakano et al. 2000), including humans (Ikonomidis et al. 
1997).   
The protective effects of preconditioning exist in 2 distinct phases.  The first, defined as early 
phase preconditioning, provides the heart with protection from ischemic insults within 2 – 3 
hours of the preconditioning stimulus.  The second, defined as late phase preconditioning, 
provides the heart with protection between 24 and 72 hours following the preconditioning 
stimulus (Penna et al. 2009).  The mechanisms involved are separate and discrete in these 2 time 
periods, but the stimuli can be the same.  Importantly, ROS activate pathways of both phases of 
protection (Sindram et al. 2002; Vanden Hoek et al. 1998), illustrating their central role in 
preconditioning the myocardial response to ischemia-reperfusion injury.  When ROS scavengers 
are used during the ischemic preconditioning protocol the cardioprotective effect disappears (Sun 
et al. 1996; Baines et al. 1997).  Interestingly, without an ischemic stimulus, hearts can be 
preconditioned  solely with an increase in intracellular ROS; both pharmacologically generated 
ROS (Baines et al. 1997) and the addition of exogenous ROS (Tritto et al. 1997) induce a 
comparable preconditioning effect. 
In response to a ROS preconditioning stimulus, the oxidative stress handling ability of the 
cell increases, which may allow the myocardium to survive future ischemia-reperfusion-induced 
ROS generation (Das et al. 1992; Rudiger et al. 2003).  This adaptation occurs in the late phase 
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of preconditioning and is due mainly to increased de novo protein synthesis of protective 
antioxidant enzymes (Bolli 2000).  The amount of enzymatic antioxidants increases 24 hours 
after ischemic preconditioning in dog hearts in vivo (Hoshida et al. 1993) and cultured rat 
cardiomyocytes (Yamashita et al. 1994), and this increase has been attributed to the ROS 
stimulus (Maulik et al. 1995).  This increase in enzymatic antioxidants has been observed 
following pharmacological (Maulik et al. 1995), exercise induced (Yamashita et al. 1999), and 
heat stress-induced (Yamashita et al. 1998) preconditioning, and these changes correlated with 
reductions in susceptibility to ischemia-reperfusion injury.  However, it is important to note that 
conflicting results have been reported in vivo using pig (Tang et al. 1997) and rabbit (Tang et al. 
2000) models of ischemic preconditioning, suggesting that this mechanism may behave 
differently in vivo.   
 
2.9. Effect of n-3 HUFA Intake on Blood and Tissue Levels 
The blood and tissue levels of EPA and DHA are determined by the amount and frequency of 
their intake, and different tissues and blood pools respond to EPA and DHA intake in different 
ways.  In the blood, the plasma fraction responds most rapidly to DHA intake (Metherel et al. 
2009).  EPA and DHA accretion also varies across different tissues (Rodrigues et al. 2014), and 
depends on both the accretion of EPA and DHA and their half-life within the tissue itself.    
In animal studies, the intake of EPA and DHA results in blood and heart accretion, and this 
has been shown to occur as early as 72 hours following the initiation of intake in a study 
employing fish oil infusion (McGuinness et al. 2006).  Other studies employing longer term 
dietary interventions with modified chow diets or daily gavage have similarly demonstrated 
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increased blood and myocardial EPA and DHA concentrations (Zeghichi-Hamri et al. 2010; 
Force et al. 1989; Castillo et al. 2013).   
Intake patterns in humans differ, as the sources of EPA and DHA in an unsupplemented diet 
are typically consumed intermittently, although the regularity of EPA and DHA intake can be 
increased in individuals consuming supplements.  However, adherence has been reported to be 
poor in study participants advised to increase EPA and DHA intake through regular 
supplementation (Patterson et al. 2014).  It has been hypothesized that participants engage in 
compensatory supplementation patterns characterized by periods of decreased intake between 
visits and larger intakes immediately preceding assessment visits (Patterson et al. 2014).  This 
pattern results in increases in plasma levels of EPA and DHA and erythrocyte levels of EPA.  
However, erythrocyte DHA remains depressed, as the inner membrane DHA pool takes longer to 
remodel to EPA and DHA intake whereas EPA remodelling of the outer membrane is rapid 
(Metherel et al. 2009).  Such intake patterns may partly explain the negative results observed in 
clinical trials testing cardioprotection while employing fish oil supplementation (Kwak et al. 
2012; Rizos et al. 2012). 
In an acute feeding protocol it is therefore important to determine at what time, and in what 
molecular form, DHA enters the plasma and myocardium and can thus influence heart function.  
Postprandial plasma levels of n-3 HUFA in humans peak between  4 (Hanwell et al. 2009) and 6 
(Harris et al. 2013) hours after ingestion, with levels declining, but remaining elevated relative to 
baseline, for at least 24 hours (Yang et al. 2012).  The effect on the plasma phospholipid pool in 
humans is comparatively delayed, with DHA levels not reaching a peak until 24 hours after 
ingestion in this pool (Raatz et al. 2009).   
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The amount of DHA provided is an important consideration in order to ensure appreciable 
increases in plasma and left ventricle concentrations.  In Sprague-Dawley rats the intake of 0.96 
g of DHA per day for 8 weeks increased erythrocyte DHA, which has been considered as a 
marker for myocardial DHA accretion (Zeghichi-Hamri et al. 2010).  This intake ranged from 
0.64 to 0.27 mg/g body weight per day as the body weight of the animals increased, but the 
absolute DHA dose remained constant throughout the protocol.   
 
2.10. Sex Differences in Cardiovascular Disease and n-3 HUFA 
Sex differences in both ischemia-reperfusion injury (Bae & Zhang 2005) and DHA 
metabolism (Kitson et al. 2012) have been observed.  Given initiatives and policies aimed at 
improving understandings of the effect of sex in health and disease (Clayton & Collins 2014; 
Health Canada 2009) it is important to examine the potential role of sex on the outcomes of this 
thesis.    
Laboratory investigations in animals have demonstrated that females experience less 
ischemia-reperfusion injury in models of regional (Brown et al. 2005; Chicco et al. 2007; 
Edwards et al. 2009; Johnson et al. 2006; Song et al. 2003) and global (Bae & Zhang 2005) 
myocardial ischemia.  Decreased oxidative stress (Barp et al. 2002) and reduced production of 
ROS (Lagranha et al. 2010) in female hearts have been observed, possibly contributing to this 
effect. 
The effect of preconditioning is also sex-dependent, as pre-menopausal females experience 
less protection from infarction following both traditional ischemic (Song et al. 2003; Turcato et 
al. 2006) and exercise-induced (Chicco et al. 2007) preconditioning protocols.  This effect 
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appears to be dependent on age, as 18 week old mice experienced preconditioning while 10 week 
old mice did not (Turcato et al. 2006).     
Sex differences can also influence the content of n-3 HUFA in rat hearts.  Chow-fed female 
rats have higher levels of DHA in several tissues including the heart as compared with males 
(Kitson et al. 2012).  Sex hormones alter metabolism of fatty acids and DHA specifically as 17β-
estradiol (Kitson et al. 2012) and progesterone (Childs et al. 2012; Sibbons et al. 2014) have 
been implicated in increases in hepatic desaturases.  This effect is observable in humans, as 
tracer studies have demonstrated increased conversion of α-linolenic to the longer chain products 
EPA and DHA acid in females as compared with males (Pawlosky et al. 2003; Burdge et al. 
2002; Burdge & Wootton 2002).   
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Chapter 3 
Rationale and Objectives 
3.1. Rationale 
N-3 HUFA are associated with reduced cardiovascular disease, and one of the 
cardioprotective mechanisms likely involves the reduction of ischemia-reperfusion injury. The 
role of n-3 HUFA in acute and chronic cardioprotection has been extensively studied, but recent 
studies (Abdukeyum et al. 2008; McGuinness et al. 2006) as well as investigations in our lab 
(Smith et al. 2012) have suggested that n-3 HUFA may also act  like preconditioning agents, 
possibly through oxidative stress pathways.  Late phase preconditioning protects the myocardium 
from ischemia-reperfusion injury as early as 24 hours after the preconditioning stimulus and 
depends on the de novo synthesis of protective proteins including enzymatic antioxidants.  
Currently no information exists regarding the potential of acute n-3 HUFA intake to effect 
adaptions in left ventricular function and ischemic susceptibility in the late phase window of 
traditional preconditioning.  This is particularly relevant given the acute intake patterns observed 
in humans, and may help to explain the discordance between positive laboratory findings and 
their translation to cardioprotection in clinical populations.  Important sex differences in n-3 
HUFA content and oxidative stress capacity also exist which may influence the cardiovascular 
effects of acute n-3 HUFA intake and should therefore be characterized.   
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3.2. Statement of Objectives 
This thesis aimed to understand the effects of acute DHA intake on myocardial function and 
susceptibility to ischemia-reperfusion injury.  Parameters pertaining to the experimental model 
used, including type of perfusion, rat strain, and ischemic duration were first optimized prior to 
the investigation of acute DHA intake.  The left ventricular contractile and coronary vascular 
functional response to acute DHA intake was then characterized in the Langendorff isolated 
heart model.  Additionally, the potential role of DHA mediated cardioprotection through late 
phase preconditioning was investigated using an established ischemia-reperfusion protocol.  
Lipid analysis was employed in order to understand the dynamics of DHA intake and myocardial 
incorporation in this acute time frame.  Comprehensive measures of the beat-by-beat left 
ventricular contractile parameters and the function of the coronary vasculature were made.  
Protection from ischemia-reperfusion injury was assayed using both the recovery of heart 
functional parameters and biochemical staining techniques.  Measures of the protein content of 
enzymatic antioxidants in the left ventricle were made to determine the extent of antioxidant 
system adaptations. 
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3.3. Hypotheses 
1. Increasing ischemia durations will result in an increasing degree of myocardial functional 
impairment and infarction 
2. Acute intake of DHA will increase plasma and left ventricular myocardium DHA content 
3. Rats supplemented with an acute dose 0.4 mg/g body weight of DHA 24 hours prior to 
the ischemia-reperfusion protocol will be less susceptible to myocardial functional 
impairment and infarction following ischemia-reperfusion 
4. Females will respond less than males to acute DHA-mediated protection from ischemia-
reperfusion injury 
5. The protein content of the enzymatic antioxidants CuZnSOD, MnSOD, and GPx will be 
increased in myocardial samples from DHA treated animals relative to control 
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Chapter 4 
Analytical Techniques 
4.1. Animals, Diets, and Interventions 
Animal procedures conformed to the standards set by the Canadian Council on Animal Care 
and were approved by the University of Waterloo Animal Care Committee.  Sprague-Dawley 
and Wistar inbred rats were ordered from Harlan Laboratories (Mississauga, Ontario).  Animals 
were group housed in the Department of Kinesiology facility in temperature and humidity 
controlled conditions on a reversed 12:12 hour light-dark cycle.  Experimental animals were 
maintained on standard rat chow diets (Harlan Teklad 8640, fatty acid composition listed in 
Table 1) and had access to food and water ad libitum.  In DHA feeding studies, animals were 
given a single oral gavage of 0.4 mg DHA/g body weight in the form of DHASCO oil (DSM, 
The Netherlands, fatty acid composition listed in Table 2).  An equivalent volume of 
commercially available soybean oil was used as a control as soybean oil is the primary source of 
fatty acids in the Harlan Teklad 8640 diet, and therefore the control oil closely mirrored the fatty 
acid composition of the diet.  Animals that were fed with an oral gavage 24 hours prior to 
isolated heart experiments were fed at a consistent time of day and subsequently transferred to 
individual cages to allow for fasting prior to experimentation.   
 
4.2. Langendorff Isolated Heart Perfusion Protocol 
Animals were anaesthetized by 1:3 sodium pentobarbital: 0.9% sterile saline administered by 
intra-peritoneal injection.  Hearts were excised rapidly by median thoracotomy and placed into 
cold (<4°C) Krebs-Henseleit buffer briefly. Excised hearts were then cannulated in retrograde by 
the ascending aorta and fixed in place with silk sutures.  A small incision was made in the left 
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atrium through which an intraventricular balloon catheter was passed to the floor of the left 
ventricle.  The intraventricular balloon was then filled with degassed water and left ventricular 
diastolic pressure was set at 10 mmHg.     
The heart was perfused with a modified Krebs-Henseleit bicarbonate buffer containing (in 
mM/L) 118 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 10 glucose, 2.5 CaCl2, and 2.5 NaHCO3.  
This was buffered to a pH of 7.40 at 37°C and oxygenated with 95% O2 - 5% CO2.  Two distinct 
perfusion methods were used for the investigations in this thesis: constant flow (Chapter 5 & 6) 
and constant pressure perfusion (Chapter 7).  In constant flow perfusion, a peristaltic pump and 
ultrasonic flow sensor are used to establish a constant rate of flow based on the animal’s body 
weight and estimated coronary flow in vivo.  The flow remains constant throughout the 
experiment, thus overriding the coronary vasculature’s autoregulatory function.  Conversely, in 
constant pressure perfusion, the hydrostatic pressure of the buffer reaching the heart is kept 
constant and the flow rate is controlled physiologically by the coronary vascular tone. 
A 30 minute baseline period was used to allow cardiac function to normalize to the perfusion 
conditions.  Exclusion criteria were established a priori as this is recommended for Langendorff 
isolated heart perfusion (Bell et al. 2011).  They included a heart rate <175 beats per minute, 
developed pressure <50 mmHg, rate of contraction <2000 mmHg/s, and rate of relaxation >-
1000 mmHg/s at baseline.  Global ischemia was initiated by shutting off flow at the peristaltic 
pump and closing a valve proximal to the heart.  Reperfusion was initiated following ischemia by 
opening the valve and re-establishing the flow rate using the peristaltic pump.  Following the 
Langendorff protocol, hearts were removed from the system and placed immediately into cold 
(<4°C) Krebs-Henseleit buffer at a pH of 7.40.  The aorta and atria were removed and hearts 
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were subsequently wrapped tightly in cellophane and aluminum foil and frozen in a -80°C 
freezer for further analysis.     
 
4.3. Quantifying Myocardial Ischemia-Reperfusion Injury 
Myocardial response to nutritional intervention and ischemia-reperfusion was determined by 
measuring the recovery of functional performance of the coronary vasculature and left ventricle, 
as well as biochemical assays of the myocardium.  Parameters of heart function were measured 
continuously throughout the protocol (Powerlab/4SP and Chart version 5.5.1, ADInstruments, 
New Zealand), with baseline measures taken in the final minute of the 30 minute normalization 
period.  Frozen whole heart samples were sliced transversely into 1 mm thick slices.  These were 
incubated in a 1% w/v solution of 2,3,5-triphenyltetrazolium chloride (TTC) in phosphate buffer 
(88 mM Na2HPO4 , 1.8 mM NaH2PO4, pH=7.4) at 37°C for 20 minutes.  TTC staining 
identifies viable tissue as active myocardial dehydrogenase enzymes produce red formazan-
insoluble coloured pigments in a redox reaction (Schwarz et al. 2000).  Unstained areas are 
assumed to lack dehydrogenase enzyme activity and are considered to be nonviable, infarcted 
tissue.  Stained slices were visualized under a dissection microscope and images were captured 
using a digital camera.  These were processed using ImageJ software (NIH public domain, 
http://rsbweb.nih.gov/ij) to quantify the unstained infarcted area as a percentage of the total 
myocardial volume.   
 
4.4. Analysis of Fatty Acids 
Fatty acids were analyzed as previously described (Metherel et al. 2012).  Briefly, lipids were 
extracted from left ventricular myocardium samples and rodent chow diets according to the 
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Folch method (Folch et al. 1957).  Samples were mixed with 2:1 chloroform methanol (v/v) 
containing 50 μg/ml butylated hydroxyl toluene (BHT) and docosatrienoic acid (C 22:3n-3) ethyl 
ester (Nu-chek Prep Inc., Elysian, MN, USA) as an internal standard for absolute concentration 
determinations and 500 μL of 0.2 M Na2PO4 buffer was added.  Samples were inverted and 
centrifuged at 1734 rcf for 5 minutes and the organic phase was collected and total lipid extracts 
were stored at -80°C until further analysis.   
Fatty acid methyl esters were prepared through the use of 14% BF3 in methanol and heating 
at 85°C for 1 hour of isolated total lipid extracts (Morrison & Smith 1964). Direct 
transesterification procedures without prior lipid extraction were used to prepare fatty acid 
methyl esters from plasma and gavage oil.  Fatty acid methyl esters were analyzed by gas 
chromatography using a Varian 3900 gas chromatograph (Varian Inc, Mississauga, ON, Canada) 
with a DB-FFAP capillary column with 15 m × 0.10 mm injected dose × 0.10 μm film thickness, 
polyethylene glycol capillary column (J & W Scientific, Agilent Technologies, Palo Alto, CA) 
with H2 carrier gas flowing at 30 mL/min.  Fatty acid concentrations were quantified through 
comparison with the internal reference standard docosatrienoic acid.   
 
4.5. Statistical Analysis 
Statistical analyses were performed using Graphpad Prism for Windows version 6.0 and 
SPSS for Windows version 11.5.  Isolated heart vascular and left ventricular functional variables 
were compared using independent T-tests at individual timepoints.  Area under the curve data 
was compared using 1 way ANOVA.  A priori comparisons between functional variables across 
each time point were additionally analyzed with an unpaired t-test.  Fatty acid data was analysed 
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by a multivariate general linear model.  Statistical significance was determined at an α-level of 
0.05. 
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Values are mean ± SD from triplicate analysis.  SFA: saturated fatty acids, MUFA: 
monounsaturated fatty acids, PUFA: polyunsaturated fatty acids. 
 
 
Table 1.  Fatty Acid Composition of Diet 
Fatty Acid μg Fatty Acid/mg diet 
Percent of Total Fatty 
Acids in Diet 
C 10:0 0.79 ± 1.75 nd 
C 12:0 0.08 ± 0.03 0.13 ± 0.03 
C 14:0 0.22 ± 0.04 0.33 ± 0.01 
C 16:0 8.91 ± 1.53 13.46 ± 0.35 
C 17:0 0.09 ± 0.01 0.14 ± 0.01 
C 18:0 1.56 ± 0.26 2.47 ± 0.91 
C 20:0 0.22 ± 0.02 0.34 ± 0.03 
C 22:0 0.21 ± 0.01 0.33 ± 0.06 
C 23:0 0.04 ± 0.01 0.06 ± 0.01 
C 24:0 0.13 ± 0.01 0.20 ± 0.06 
SFAs 11.53 ± 1.40 17.54 ± 0.71 
C 12:1 nd nd 
C 14:1 0.01 ± 0.01 0.01 ± 0.01 
C 16:1 0.47 ± 0.25 0.72 ± 0.35 
C 18:1n-7 0.94 ± 0.12 1.43 ± 0.06 
C 18:1n-9 13.93 ± 2.13    21.10 ± 0.13 
C 20:1n-9 0.20 ± 0.02 0.31 ± 0.03 
C 22:1n-9 0.04 ± 0.01 0.06 ± 0.01 
C 24:1n-9 0.02 ± 0.01 0.03 ± 0.01 
MUFAs 15.61 ± 2.33 23.66 ± 0.43 
C 18:2n-6 32.87 ± 4.93 49.80 ± 0.20 
C 18:3n-6 0.02 ± 0.01 0.02 ± 0.01 
C 20:2n-6 0.03 ± 0.01 0.05 ± 0.01 
C 20:3n-6 0.02 ± 0.01 0.03 ± 0.01 
C 20:4n-6 0.09 ± 0.01 0.13 ± 0.03 
C 22:2n-6 0.02 ± 0.01 0.03 ± 0.01 
C 22:4n-6 0.02 ± 0.01 0.02 ± 0.01 
C 22:5n-6 0.02 ± 0.01 0.03 ± 0.01 
N-6 33.08 ± 4.94 50.12 ± 0.22 
C 18:3n-3 3.77 ± 0.57 5.72 ± 0.05 
C 20:3n-3 0.01 ± 0.01 0.01 ± 0.01 
C 20:5n-3 0.14 ± 0.02 0.21 ± 0.01 
C 22:5n-3 0.03 ± 0.01 0.05 ± 0.01 
C 22:6n-3 0.15 ± 0.01 0.23 ± 0.05 
N-3 4.10 ± 0.59 6.22 ± 0.09 
Total 64.32 ± 9.24 97.54 ± 1.18 
  
29 
 
Table 2.  Fatty Acid Concentration of Gavage Oils 
Fatty Acid μg fatty acid/mg oil 
 Soybean Oil DHASCO 
C 10:0 0.29 ± 0.02 6.88 ± 1.16 
C 12:0 0.23 ± 0.05 54.99 ± 1.40 
C 14:0 1.06 ± 0.06 150.91 ± 2.97 
C 16:0 123.03 ± 2.51 128.80 ± 3.65 
C 17:0 1.07 ± 0.03 0.57 ± 0.08 
C 18:0 48.18 ± 0.59 6.92 ± 0.15 
C 20:0 3.61 ± 0.10 0.92 ± 0.10 
C 22:0 3.04 ± 0.18 1.27 ± 0.06 
C 23:0 0.33 ± 0.13 0.19 ± 0.04 
C 24:0 1.12 ± 0.17 0.88 ± 0.64 
SFAs 183.13 ± 2.80 353.08 ± 6.34 
C 12:1 0.05 ± 0.04 0.12 ± 0.03 
C 14:1 0.11 ± 0.06 3.48 ± 0.15 
C 16:1 2.33 ± 0.21 31.10 ± 1.48 
C 18:1n-7 19.93 ± 0.15 4.80 ± 0.56 
C 18:1n-9 257.33 ± 3.56 186.10 ± 6.40 
C 20:1n-9 1.69 ± 0.07 0.48 ± 0.03 
C 22:1n-9 0.68 ± 0.06 0.57 ± 0.06 
C 24:1n-9 0.13 ± 0.05 3.44 ± 1.10 
MUFAs 282.43 ± 3.04 230.39 ± 7.90 
C 18:2n-6 583.49 ± 17.75 6.53 ± 0.13 
C 18:3n-6 0.11 ± 0.05 0.06 ± 0.01 
C 20:2n-6 0.46 ± 0.03 0.06 ± 0.07 
C 20:3n-6 0.08 ± 0.02 0.07 ± 0.02 
C 20:4n-6 0.12 ± 0.13 0.09 ± 0.06 
C 22:2n-6 0.13 ± 0.10 0.06 ± 0.04 
C 22:4n-6 0.08 ± 0.05 0.05 ± 0.01 
C 22:5n-6 0.05 ± 0.01 0.07 ± 0.03 
N-6 584.52 ± 17.90 7.00 ± 0.21 
C 18:3n-3 66.18 ± 2.90 0.61 ± 0.05 
C 20:3n-3 0.09 ± 0.06 0.05 ± 0.01 
C 20:5n-3 0.07 ± 0.07 0.19 ± 0.05 
C 22:5n-3 0.06 ± 0.01 3.92 ± 0.17 
C 22:6n-3 0.07 ± 0.01 337.50 ± 6.90 
N-3 66.47 ± 2.93 342.27 ± 7.12 
Total 1116.54 ± 23.59 932.75 ± 10.03 
Values are mean ± SD from triplicate analysis.  SFA: saturated fatty acids, MUFA: 
monounsaturated fatty acids, PUFA: polyunsaturated fatty acids. 
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Chapter 5 
Sex Differences in Response to Acute DHA Feeding in Sprague-Dawley Rats 
 
5.1. Introduction 
Several sex differences in cardiovascular physiology and fatty acid metabolism exist which 
may result in differential effects of acute DHA feeding in males and females.  Females are less 
susceptible to ischemia-reperfusion injury (Bae & Zhang 2005), demonstrate increased resistance 
to myocardial oxidative stress (Lagranha et al. 2010), and have higher myocardial DHA content 
(Kitson et al. 2012) than males.  Females are also less responsive to ischemic preconditioning 
induced-cardioprotection, which depends on an oxidative stress stimulus to initiate 
cardioprotective adaptations (Song et al. 2003; Turcato et al. 2006).  Therefore, the effect of 
acute DHA intake on susceptibility to myocardial ischemia-reperfusion injury may be sex-
dependent.    
 
5.2. Study Protocols 
Standard chow-fed male and female Sprague-Dawley rats (3 – 4 months of age, n = 10 per 
sex, diet composition detailed in Table 1) were gavaged with a single dose of oil normalized to 
body weight.  The treatments were either algal-derived high DHA oil, providing 0.4 mg DHA/g 
body weight (0.339 mg DHA/μL oil), or an equivalent volume of soybean oil as a control.  
Following gavage, rats were returned to their cages and had ad libitum access to food and water 
for 12h and were then fasted for an additional 12h.  Animals were then anaesthetized with 
intraperitoneal sodium pentobarbital, instrumented in the Langendorff isolated heart system, and 
perfused at a constant flow normalized to body weight.  In this study a normalization period of 
30 minutes was used, followed by 30 minutes of global ischemia and 90 minutes of reperfusion.  
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Left ventricular function and vascular performance parameters were measured continuously 
throughout the protocol.  Hearts were then collected, frozen at -80°C, and analysed for infarction 
by TTC staining.  
 
5.3. Results 
Fourteen animals are included in the final analyses as 4 animals could not be instrumented 
due to technical difficulties with heart perfusion and 2 animals were excluded due to baseline left 
ventricular function that was below the a priori exclusion criteria.  Therefore, the number of 
animals included in the analysis per group were: male control (3), male DHA (4), female control 
(4), female DHA (3).  There was no effect of DHA treatment on animal weight (p>0.05), but 
males had significantly greater body weight than females (p<0.0001).   
The ischemic stimulus used in these studies did not result in significant impairment of left 
ventricular function as compared with baseline values.  In fact, recovery of hemodynamic 
function immediately following the ischemia-reperfusion protocol was actually higher than 
baseline (Figures 1 – 7). 
The hearts of DHA-fed males had lower left ventricular function at baseline relative to male 
controls, but this affect was not observed in females (summarized in Table 3).  Acute DHA 
feeding caused reduced left ventricular rate of contraction and rate of relaxation in male rats at 
baseline (p<0.05).  There was also a trend towards reduced left ventricular developed pressure 
(p=0.058) and systolic pressure (p=0.064) although this did not reach statistical significance.  
There was no significant effect of DHA feeding at baseline on female heart function in any of the 
functional parameters measured.   
Male control rats had significantly higher left ventricular function than female control 
animals, including increased developed pressure (Figure 1), rate of contraction (Figure 2), and 
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rate of relaxation (Figure 3) (p<0.05).  Treatment with DHA appeared to eliminate left 
ventricular functional differences between male and female rats, as the male DHA treated hearts 
demonstrated reduced contractile function.  As a result, there were no significant differences in 
left ventricular function between DHA treated males and either control or DHA treated females 
at baseline (p>0.05). 
DHA-induced impairment of cardiac function persisted following ischemia into the 
reperfusion period, where DHA treatment was associated with approximately 25% reduced 
developed pressure compared with controls in males (Figure 1A).  Rate of contraction (Figure 
2A), rate of relaxation (Figure 3A), and systolic pressure (Figure 6A) during reperfusion were 
also lowered in the DHA treated male hearts compared with controls.  By normalizing data to 
baseline values to eliminate the effect of baseline differences, it was determined that the percent 
recovery of heart contractile function was greater in the DHA treated hearts.  Male hearts 
exhibited increased recovery of rate of contraction (Figure 2C), rate of relaxation (Figure 3C), 
and heart rate (Figure 4C).  Therefore, despite lower absolute left ventricular function during 
reperfusion, the DHA treated animals actually recovered a greater percent of their baseline 
function following the ischemic stimulus.  This protective effect of DHA on left ventricular 
function was only observed in males, as the percent recovery of contractile function in females 
was not affected. 
There was no effect of DHA treatment or sex on coronary perfusion pressure (Figure 7).  
DHA also did not appear to have a protective effect on myocardial contracture.  In fact, DHA 
actually appeared to worsen contracture, as hearts from male rats treated with DHA actually had 
significantly increased end diastolic pressure during and immediately following ischemia (Figure 
5A, p<0.05).  There was no effect of DHA treatment on contracture in females (Figure 5B). 
  
33 
 
The effect of DHA on preservation of hemodynamic function in males, but not females, was 
not supported by infarction data as measured with TTC staining, as there was no effect of DHA 
treatment on infarction in male or female animals (Figure 8, p>0.05).  However, when males and 
females were pooled together, there was a significant overall effect of DHA treatment on 
infarction independent of sex (p<0.05).   There were additionally no significant differences in 
infarction damage between male and female Sprague-Dawley rats (p>0.05). 
 
5.4. Discussion 
These data suggest that the female response to DHA treatment differs markedly from males.  
Female hearts did not demonstrate increased recovery of any left ventricular functional 
parameters with DHA treatment.  Baseline left ventricular functional differences with treatment, 
which were apparent in males, also did not occur in female hearts.   
It was observed that DHA reduced baseline left ventricular function in males independent of 
the ischemia-reperfusion protocol.  This impairment was observed in the rate of contraction and 
rate of relaxation, while there was also a trend towards reduced baseline developed pressure that 
did not reach significance.  Baseline left ventricular function is dependent on numerous 
physiological systems, and the responses of the different functional variables measured in these 
studies provide some information as to the specific systems that are affected by DHA treatment.  
Rate of contraction is due to both the coupling of Ca
2+
-induced Ca
2+
 release and the sensitivity of 
the myofilaments to Ca
2+
.  Myofilament Ca
2+
 sensitivity is reduced under conditions of oxidative 
stress (Suzuki et al. 1991).  As DHA has been shown to increase cellular oxidative stress (Farina 
et al. 2003), it may have contributed to reduced left ventricular function through reductions in 
Ca
2+ 
sensitivity. 
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The rate of relaxation is dependent on the removal of cytosolic Ca
2+
, which proceeds mainly 
through 2 pathways in the murine myocardium, SERCA and NCX (Bassani et al. 1994).  SERCA 
is the most dominant method for Ca
2+
 sequestration in rat cardiomyocytes, contributing ~92% of 
the Ca
2+ 
sequestration capacity, with minimal contributions from the NCX and slow systems 
(Bers 2002; Bassani et al. 1994).  SERCA function is impaired following ischemia-reperfusion 
injury (Temsah et al. 1999), as it is highly susceptible to oxidative stress and its function is 
reduced when specific sulfhydryl groups are oxidized (Scherer & Deamer 1986).  Reduced 
SERCA activity could reduce the rate of removal of cytosolic Ca
2+
, thus lowering the left 
ventricular rate of relaxation. 
The developed pressure of the isolated heart is dependent on a combination of both the 
calcium sensitivity and the rate of relaxation, and since it takes into account both systolic and 
diastolic pressure it is indicative of contraction and relaxation mechanisms.  Developed pressure 
could be reduced through a reduction in overall cytosolic Ca
2+ 
during systole, reduced 
sequestration of cytosolic Ca
2+ 
during diastole, or a reduction in myofilament Ca
2+ 
sensitivity.  
As mentioned previously, oxidative stress can result in impairment in all 3 of these mechanisms, 
potentially resulting in depression of developed pressure in the isolated heart.   
The effect of DHA treatment on left ventricular hemodynamics was sex-dependent, as no 
differences were seen in female rats.  Females have higher innate levels of EPA and DHA in 
several tissues including the myocardium (Kitson et al. 2012).  Female hearts additionally have 
increased oxidative stress handling capacity as compared with males, with increased myocardial 
levels of the enzymatic antioxidant SOD and reduced lipid peroxidation (Barp et al. 2002).  
Thus, if baseline functional differences were caused by increases in oxidative stress brought on 
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by DHA, this stressor may have been eliminated by the innately higher antioxidant defences in 
the female rats. 
This study demonstrates that DHA decreases infarction damage following a single dose 
independent of sex.  There was no significant effect in males and females when analyzed 
independently, but this may be due to reduced power due to low animal numbers.  Evidence in 
the literature is mixed as to the role of DHA in reducing myocardial infarction, with some studies 
describing a reduction in myocardial infarction (Castillo et al. 2013; Zeghichi-Hamri et al. 2010) 
while others have reported no effect (Force et al. 1989).  Protocol differences between these 
studies, including perfusion method and animal strain, may partially explain these contradictory 
results.   
Previous reports in the literature have described increased infarction damage in males as 
compared with females (Edwards et al. 2009; Chicco et al. 2007; Bae & Zhang 2005).  
Conflictingly, the current study did not detect such a difference.  This may be related to 
methodological factors, as there are a number of variables which differ between these studies, 
including animal species and strain, perfusion method used, and ischemic duration.  
Additionally, animal age may play some role, as sex-difference in cardiovascular function 
between males and females have been shown to dissipate with age.  While there are significant 
differences in the response to ischemic preconditioning in 10 week old mice, these differences 
were no longer apparent at 18 weeks (Turcato et al. 2006).   
Left ventricular function was higher than baseline following 30 minutes of global ischemia, 
indicating minimal hemodynamic impairment with the ischemic stimulus used.  This observation 
conflicts with reports in the literature employing Sprague-Dawley rats with similar durations of 
global ischemia (Maddika et al. 2009; Bae & Zhang 2005), where significant impairment relative 
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to baseline was observed.  This may be attributable to protocol differences between studies.  One 
possibility is temperature regulation, as reduced temperature in the Langendorff preparation is 
known to be cardioprotective (Bell et al. 2011).  Although water bath temperatures were 
controlled in these experiments, the temperature in the heart chamber and heart itself may have 
been lower than the target 37°C, resulting in reduced impairment from the ischemia-reperfusion 
protocol.  The degree of functional impairment is also dependent on ischemic duration (Wang et 
al. 2001) and animal strain (Javouhey et al. 1989), and thus it may be possible to achieve 
demonstrable functional impairment by varying these parameters.   
In conclusion, these results demonstrate a sex-dependent effect of DHA on left ventricular 
function at baseline and functional recovery following ischemia-reperfusion injury.  They do not 
support sex differences in infarction which have previously been demonstrated in the literature, 
but do indicate a protective effect of DHA on infarction independent of sex.  Protocol issues may 
have contributed to observations of greater left ventricular functional recovery following 
ischemia, and these should be investigated further to achieve demonstrable functional 
impairment. 
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Table 3.  Baseline Effect of DHA Treatment in Sprague-Dawley Isolated Hearts 
 Male Female 
 Control DHA Control DHA 
Developed 
Pressure 
127.9 ± 5.9 80.0 ± 12.8 83.0 ± 6.1 65.8 ± 3.7 
Systolic 
Pressure 
133.8 ± 5.7 87.5 ± 13.0 88.1 ± 6.2 71.7 ± 2.5 
Diastolic 
Pressure 
5.9 ± 0.6 7.5 ± 0.8 5.1 ± 0.8 5.8 ± 1.6 
Rate of 
Contraction 
4519.4 ± 473.2 2809.0 ± 371.4* 2501.5 ± 244.6 2598.5 ± 248.0  
Rate of 
Relaxation 
2453.8 ± 135.7 1374.5 ± 212.5* 1520.5 ± 133.9 1233.7 ± 125.1 
Heart Rate 242.8 ± 16.7 253.6 ± 13.5 214.7 ± 14.0 273.0 ± 18.3 
Perfusion 
Pressure 
60.5 ± 0.5 79.4 ± 16.2 113.6 ± 4.6 103.7 ± 8.8 
Coronary 
Flow 
15.5 ± 0.1 15.3 ± 0.2 12.3 ± 0.3 12.2 ± 0.1 
* indicates significantly different (p<0.05) from control at that timepoint by unpaired t-test. 
Values are expressed as mean ± S.E.M. (n=3 for male control and female DHA, n=4 for female 
control and male DHA). 
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Figure 1.  Left ventricular developed pressure in male and female Sprague-Dawley rats exposed 
to either a DHA or control soybean oil gavage 24 hours before experimentation.  Developed 
pressure is an index of the hearts ability to generate force and is calculated as the difference 
between systolic and diastolic pressure.  Figures A and B denote absolute pressure data while 
Figures C and D are normalized to baseline and therefore indicate percent recovery following 
ischemia.* indicates significantly different (p<0.05) from control at that timepoint by unpaired t-
test. Values are expressed as mean ± S.E.M (n=3 for male control and female DHA, n=4 for 
female control and male DHA). 
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Figure 2.  Left ventricular rate of contraction in male and female Sprague-Dawley rats exposed 
to either a DHA or control soybean oil gavage 24 hours before experimentation.  Figures A and 
B denote absolute pressure data while Figures C and D are normalized to baseline and therefore 
indicate percent recovery following ischemia.  * indicates significantly different (p<0.05) from 
control at that timepoint by unpaired t-test. Values are expressed as mean ± S.E.M. (n=3 for male 
control and female DHA, n=4 for female control and male DHA). 
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Figure 3.  Left ventricular rate of relaxation in male and female Sprague-Dawley rats exposed to 
either a DHA or control soybean oil gavage 24 hours before experimentation.  Figures A and B 
denote absolute pressure data while Figures C and D are normalized to baseline and therefore 
indicate percent recovery following ischemia.  * indicates significantly different (p<0.05) from 
control at that timepoint by unpaired t-test. Values are expressed as mean ± S.E.M. (n=3 for male 
control and female DHA, n=4 for female control and male DHA). 
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Figure 4.  Heart rate of male and female Sprague-Dawley rats exposed to either a DHA or 
control soybean oil gavage 24 hours before experimentation.  Figures A and B denote absolute 
pressure data while Figures C and D are normalized to baseline and therefore indicate percent 
recovery following ischemia.  * indicates significantly different (p<0.05) from control at that 
timepoint by unpaired t-test. Values are expressed as mean ± S.E.M. (n=3 for male control and 
female DHA, n=4 for female control and male DHA).   
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Figure 5.  Left ventricular end diastolic pressure in male and female Sprague-Dawley rats 
exposed to either a DHA or control soybean oil gavage 24 hours before experimentation.  
Diastolic pressure is an index of cardiac damage, with higher values being associated with 
increased myocardial damage following ischemia.  Figures A and B denote absolute pressure 
data while Figures C and D are normalized to baseline and therefore indicate percent recovery 
following ischemia.  * indicates significantly different (p<0.05) from control at that timepoint by 
unpaired t-test. Values are expressed as mean ± S.E.M. (n=3 for male control and female DHA, 
n=4 for female control and male DHA). 
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Figure 6.  Left ventricular systolic pressure in male and female Sprague-Dawley rats exposed to 
either a DHA or control soybean oil gavage 24 hours before experimentation.  Figures A and B 
denote absolute pressure data while Figures C and D are normalized to baseline and therefore 
indicate percent recovery following ischemia.  * indicates significantly different (p<0.05) from 
control at that timepoint by unpaired t-test. Values are expressed as mean ± S.E.M (n=3 for male 
control and female DHA, n=4 for female control and male DHA). 
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Figure 7.  Systemic perfusion pressure in male and female Sprague-Dawley rats exposed to 
either a DHA or control soybean oil gavage 24 hours before experimentation.  Figures A and B 
denote absolute pressure data while Figures C and D are normalized to baseline and therefore 
indicate percent recovery following ischemia.  * indicates significantly different (p<0.05) from 
control at that timepoint by unpaired t-test. Values are expressed as mean ± S.E.M.  (n=3 for 
male control and female DHA, n=4 for female control and male DHA). 
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Figure 8.  Infarcted area in male and female Sprague-Dawley rats exposed to either a DHA or 
control soybean oil gavage 24 hours before experimentation.  * indicates a significant effect of 
treatment by independent T-test of pooled values (p<0.05).  Values are expressed as mean ± 
S.E.M. (n=3 for each male control and female DHA, n=4 for each female control and male 
DHA).
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Chapter 6 
Effect of Ischemic Duration on Ischemia-Reperfusion Injury in Sprague-Dawley Rats 
 
6.1. Introduction 
The duration of ischemia affects the degree of left ventricular functional impairment and 
myocardial infarction in isolated heart models (Wang et al. 2001).  It was determined in the 
previous study that 30 minutes of ischemia permits recovery of left ventricular function above 
baseline values in the model used.  Achieving demonstrable impairment following ischemia is 
essential in order to detect any changes in ischemic susceptibility from an experimental 
intervention.  Therefore, it was necessary to investigate the effects of varying ischemia durations 
on myocardial recovery in Sprague-Dawley rats perfused in constant flow.   
 
6.2. Study Protocols 
Group housed male Sprague-Dawley rats (3 – 4 months of age, n = 9) who were maintained 
on the standard chow diet were sacrificed, instrumented in the Langendorff model, and perfused 
at constant flow proportional to body weight.  Following a 30 minute baseline perfusion period, 
hearts were randomly assigned to one of the three groups: 20 minute, 30 minute, or 40 minute 
global ischemia.  Following the ischemic stimulus, hearts were reperfused for a further 90 
minutes.  Left ventricular function and coronary vascular performance parameters were 
measured continuously throughout the protocol.  Hearts were then collected, frozen at -80°C, and 
analysed for infarction by TTC staining.  
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6.3. Myocardial Response to Ischemia-Reperfusion  
Three animals per group were included in the analyses.  There were no differences in body 
weight between the ischemic duration groups (p>0.05).  As hypothesized, progressive increases 
in ischemia duration resulted in corresponding decreases in left ventricular functional 
performance during the ischemia-reperfusion protocol.  Prior to the ischemic stimulus, there 
were no significant baseline differences between any of the groups in any of the functional 
variables measured (p>0.05).   
Forty minutes of ischemia resulted in significantly greater impairment of reperfusion 
developed pressure (Figure 9) and rate of contraction (Figure 10) as compared with 20 minutes 
of ischemia, and reperfusion end diastolic pressure (Figure 11) was significantly greater than 
both 20 and 30 minute groups.  This effect was only significant in the first 15 minutes of the 
protocol, as after this point there were no group differences in left ventricular function with the 
exception of end diastolic pressure, which remained significantly elevated in the 40 minute group 
even after 120 minutes of reperfusion.  These data suggest that ischemic impairment of left 
ventricular function typically manifests in the early phase of reperfusion in this model.  Heart 
rate (Figure 12), vascular function (Figure 13), and systolic pressure (Figure 14) were not 
affected by the duration of ischemia, as these variables were not different at any point in the 
protocol (p>0.05).  Ischemia duration also did not affect the cumulative measure of area under 
the curve (AUC) for any of these variables.  Importantly, there no significant differences in 
either the left ventricular or coronary vascular function between the 20 minute and 30 minute 
groups, and therefore only the 40 minute group differed in the functional response to ischemia-
reperfusion.   
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The area under the curve response was highly variable, resulting in difficulty in determining 
statistical significance.  There was no effect of ischemia duration on the timecourse of rate of 
relaxation recovery (Figure 15).  However, rate of relaxation demonstrated significant 
cumulative differences in the reperfusion period demonstrated by reduced AUC in the 40 minute 
relative to the 20 minute group. 
Infarct size increased with increasing durations of ischemia (Figure 16).  Infarction 
measurement by TTC staining did not appear to exactly replicate the trends observed in the left 
ventricular functional variables, as 20 and 30 minute groups were not significantly different in 
their functional impairment but exhibited significantly different infarct size.  Therefore, the 
functional changes observed were not directly correlated with observations of structural changes 
in the myocardium.     
 
6.4. Discussion 
Ischemia duration was associated with increased functional impairment in some, but not all 
functional variables.  Notably, developed pressure, rate of contraction, and rate of relaxation 
were highly susceptible to ischemic duration.  Contracture, as measured by end diastolic 
pressure, was also significantly elevated with increased ischemic duration.  There was no 
significant effect of ischemic duration on heart rate.  Interestingly, increased left ventricular 
impairment with higher ischemic durations manifested in the early stages of reperfusion and 
these differences did not persist until the end of the protocol.     
Left ventricular functional impairment can be caused by the increased oxidative stress 
associated with ischemia-reperfusion (Kim et al. 2006), as it impairs myofilament Ca
2+
 
sensitivity (Suzuki et al. 1991) and ATPase-dependent Ca
2+ 
sequestration (Temsah et al. 1999).  
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Oxidative stress also induces the mitochondrial permeability transition pore to open (Halestrap et 
al. 2004) resulting in apoptotic and necrotic cell death (Gottlieb et al. 1994; Reeve et al. 2007).  
Therefore, increased oxidative stress in the 40 minute group may have contributed to the 
observed impairments in left ventricular function.      
Contracture is dependent on intracellular Ca
2+
 overload and a lack of ATP resulting in rigor-
like contraction of the myofilaments (Piper et al. 2003) and is typically used as an indicator of 
ischemia-reperfusion injury.  Increased contracture in the 40 minute ischemic group is indicative 
of increased intracellular Ca
2+
 accumulation as compared with the 20 and 30 minute group.      
Coronary vascular function was also not affected by ischemia duration, as systemic perfusion 
pressure did not differ between groups.  When using constant flow perfusion, the ability of the 
vasculature of the isolated heart to respond to ischemic conditions is removed.  For this reason, 
constant pressure perfusion is preferred for studies of ischemia-reperfusion injury (Skrzypiec-
Spring et al. 2006). 
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Figure 9. The effect of ischemia duration on left ventricular developed pressure.  Developed pressure is an index of the hearts ability 
to generate force and is calculated as the difference between systolic and diastolic pressure.  Curves were analyzed by 2 way ANOVA 
with Tukey’s multiple comparison test following a significant interaction effect.  At each individual time, points with different letters 
are significantly different (p<0.05).  AUC data was analyzed by 1 way ANOVA. Values are expressed as mean ± S.E.M. (n=3 per 
group). 
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Figure 10.  The effect of ischemia duration on left ventricular rate of contraction.  Curves were analyzed by 2 way ANOVA with 
Tukey’s multiple comparison test following a significant interaction effect.  At each individual timepoint, points with different letters 
are significantly different (p<0.05).  AUC data was analyzed by 1 way ANOVA. Values are expressed as mean ± S.E.M. (n=3 per 
group). 
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Figure 11.  The effect of ischemia duration on left ventricular end diastolic pressure.  Diastolic pressure is an index of cardiac 
damage, with higher values being associated with increased myocardial damage following ischemia.  Curves were analyzed by 2 way 
ANOVA with Tukey’s multiple comparison test following a significant interaction effect.  At each individual timepoint, points with 
different letters are significantly different (p<0.05).  AUC data was analyzed by 1 way ANOVA. Values are expressed as mean ± 
S.E.M. (n=3 per group). 
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Figure 12.  The effect of ischemia duration on heart rate.  Curves were analyzed by 2 way ANOVA with Tukey’s multiple 
comparison test following a significant interaction effect.  At each individual timepoint, points with different letters are significantly 
different (p<0.05).  AUC data was analyzed by 1 way ANOVA. Values are expressed as mean ± S.E.M. (n=3 per group). 
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Figure 13.  The effect of ischemia duration on systemic perfusion pressure.  Curves were analyzed by 2 way ANOVA with Tukey’s 
multiple comparison test following a significant interaction effect.  At each individual timepoint, points with different letters are 
significantly different (p<0.05).  AUC data was analyzed by 1 way ANOVA. Values are expressed as mean ± S.E.M (n=3 per group). 
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Figure 14.  The effect of ischemia duration on left ventricular systolic pressure.  Curves were analyzed by 2 way ANOVA with 
Tukey’s multiple comparison test following a significant interaction effect.  At each individual timepoint, points with different letters 
are significantly different (p<0.05).  AUC data was analyzed by 1 way ANOVA. Values are expressed as mean ± S.E.M. (n=3 per 
group). 
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Figure 15.  The effect of ischemia duration on left ventricular rate of relaxation.  Curves were analyzed by 2 way ANOVA with 
Tukey’s multiple comparison test following a significant interaction effect.  At each individual timepoint, points with different letters 
are significantly different (p<0.05).  AUC data was analyzed by 1 way ANOVA. Values are expressed as mean ± S.E.M. (n=3 per 
group).   
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Figure 16.  The effect of increasing ischemia duration on infarcted area in male Sprague-Dawley 
rats.  Data was analyzed by 1 way ANOVA with Tukey’s multiple comparison test following a 
significant interaction effect.  Points with different letters are significantly different (p<0.05).  
Values are expressed as mean ± S.E.M. 
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Chapter 7 
Effect of Acute DHA Feeding on Ischemia-Reperfusion Injury in Male Wistar Rats 
 
7.1. Introduction 
Wistar rats are more susceptible to ischemia-reperfusion injury as compared with Sprague-
Dawley rats (Javouhey et al. 1989).  Additionally, constant pressure perfusion is a more 
physiologically relevant model and is preferred to constant flow perfusion for studies of 
ischemia-reperfusion injury as it permits the normal autoregulatory function of the coronary 
vasculature (Skrzypiec-Spring et al. 2006).  Previous investigations demonstrated that left 
ventricular functional recovery from ischemia-reperfusion of male rats is improved relative to 
controls with a single DHA feeding after 24 hours, while there is no effect in females.  
Therefore, the effect of a single DHA feeding on ischemic susceptibility was investigated 
utilizing male Wistar rats in constant pressure perfusion. 
 
7.2. Study Protocols 
Standard chow fed male Wistar rats (3 – 4 months of age, n = 12) were gavaged with a single 
dose of oil normalized to body weight.  The treatments were either algal-derived high DHA oil 
providing 0.4 mg DHA/g body weight (0.339 mg DHA/μL oil) or an equivalent volume of 
soybean oil as a control.  Following gavage, rats were returned to their cages and had ad libitum 
access to food and water for 12h and were then fasted for an additional 12h.  Animals were 
anaesthetized at 24 hours with intraperitoneal sodium pentobarbital.  Plasma samples were 
collected prior to heart excision by drawing blood from the inferior vena cava using a needle and 
syringe.  Collected blood samples were then centrifuged at 3000 rpm for 10 minutes and the 
plasma layer was extracted and frozen at -80°C.  Total fatty acids were determined by direct 
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methylation as described in section 3.4.  Hearts were instrumented in the Langendorff isolated 
heart system and perfused at a constant pressure of 70 mmHg.  A normalization period of 30 
minutes was used, followed by 20 minutes of global ischemia and 120 minutes of reperfusion.  
Left ventricular function and vascular performance parameters were measured continuously 
throughout the protocol.  Hearts were then collected, frozen at -80°C, and analysed for infarction 
by TTC staining (Chapter 3). 
 
7.3. Myocardial Response to Ischemia-Reperfusion 
Two hearts, one each from the control and DHA group, were excluded from further analysis 
at baseline due to heart rates below the a priori exclusion criteria (<175 bpm).  Therefore 5 
animals each are included in the analyses for both the DHA and control groups.  There were no 
significant differences in body weight between DHA-treated and control animals (p<0.05). 
At 24 hours, the DHA treatment did not result in the same functional impairment that was 
observed in the Sprague-Dawley model.  There were no significant baseline differences between 
DHA treatment and control in any of the functional variables measured (p>0.05).   
DHA was associated with improved left ventricular function following the ischemic stimulus.  
During reperfusion, the left ventricular rate of contraction (Figure 17) was significantly higher in 
DHA treated rats as compared with controls.  There was a trend towards increasing reperfusion 
developed pressure in DHA treated rats, but this failed to reach significance (Figure 18).  DHA 
also affected the function of the coronary vasculature, as coronary flow during reperfusion was 
greater in DHA treated hearts as compared with controls (Figure 19).  There was no effect of 
DHA treatment on myocardial contracture as measured by diastolic pressure (p>0.05, Figure 20), 
or the rate of relaxation (Figure 21), systolic pressure (Figure 22), or heart rate (Figure 23).  
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When data was normalized to baseline (data not shown), there was no significant effect of DHA 
treatment on any of the functional variables measured.  There was no effect of DHA treatment on 
infarct size as measured by TTC staining (p>0.05, Figure 24).   
 
7.4. Plasma Fatty Acids 
Plasma n-3 HUFA were significantly elevated in the DHA group relative to control 24 hours 
following a single oral gavage in male Wistar rats (Tables 4 and 5).  Plasma DHA concentration 
(p=0.003) was significantly increased in DHA treated animals relative to controls following oral 
gavage.  Interestingly, plasma EPA significantly increased in concentration (p=0.013), even 
though the DHA gavage contains only trace amounts of EPA, suggesting the possibility of DHA 
retro-conversion to EPA.  The increase in plasma n-3 PUFAs was associated with a 
corresponding decrease in plasma n-6 PUFAs.  Arachidonic acid relative percent (p=0.025) but 
not absolute concentration (p=0.466) was reduced.  Similarly, adrenic acid (22:4n-6) relative 
percent (p=0.033) but not absolute concentration (p=0.151) was reduced.  The DHA oil also 
contains high levels of saturated fatty acids (Table 1) which did not appear to affect the plasma 
fatty acid composition.  In fact, the only difference in saturated fatty acids between control and 
DHA treatment was the decrease of the concentration of saturated fatty acid 22:0, behenic acid 
(p<0.05). 
 
7.5. Discussion 
DHA treatment increased plasma EPA and DHA levels after 24 hours.  This is in agreement 
with human studies that have demonstrated that plasma DHA peaks between 4 (Hanwell et al. 
2009) and 6 hours (Harris et al. 2013) after a single n-3 HUFA intake, with levels declining, but 
remaining elevated relative to baseline, for at least 24 hours (Yang et al. 2012).   
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Increased plasma levels of EPA and DHA may impact myocardial function through 
modulation of ion channel kinetics.  DHA interacts with, and can alter the kinetics, of the voltage 
gated L-type Ca
2+
 channel (Xiao et al. 1997) and the alpha subunit of the sodium channel (Xiao 
et al. 2001).  Isolated heart studies have demonstrated myocardial protection from ischemia-
reperfusion injury with infusion of n-3 HUFA directly into the perfusate likely demonstrating an 
effect of DHA in the free fatty acid pool (Smith et al. 2012; Richard et al. 2014).  DHA as a free 
fatty acid affected the antioxidant capacity of the myocardium by reducing lipid peroxides and 
increased expression of Notch2, part of a signalling pathway that regulates cell fate (Richard et 
al. 2014).  Increased plasma DHA can also be incorporated into tissues including the 
myocardium, where it may exert cardioprotective effects through modulation of one of the 
various mechanisms through which DHA is thought to confer cardioprotection including 
membrane structure and function, lipid mediator signalling, or oxidative-stress dependent 
preconditioning. 
DHA treatment improved left ventricular function during reperfusion in isolated hearts from 
male Wistar rats perfused at constant pressure.  The literature is mixed on whether DHA can 
improve hemodynamics following ischemia-reperfusion.  Left ventricular function recovery from 
myocardial ischemia-reperfusion was not improved following 72 hours of n-3 HUFA infusion 
(McGuinness et al. 2006) and >6 weeks of n-3 HUFA feeding (Force et al. 1989; Zeghichi-
Hamri et al. 2010).  However, other studies have demonstrated improved left ventricular function 
following both traditional ischemic preconditioning stimuli (Abdukeyum et al. 2008) and chronic 
dietary intervention with n-3 HUFA (Castillo et al. 2013; Abdukeyum et al. 2008).   
It was observed that acute DHA increased post-ischemic coronary flow, but this only 
occurred in the late stages of reperfusion, and was not evident when data was normalized to 
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baseline.  DHA has previously been shown to affect vascular function following ischemia-
reperfusion, as it improves the post-ischemic functioning of the microvasculature in the perfused 
hamster cheek pouch preparation (de Souza et al. 2015).  Dietary intake of n-3 HUFA also 
increased coronary flow following in vivo ischemia-reperfusion injury in the rat (Force et al. 
1989).  There was no effect of DHA treatment on the response of the coronary vasculature 
immediately following ischemia, indicating that DHA treatment did not affect the reactive 
hyperemic response, which is the transient increase in coronary flow following ischemia-
reperfusion that is caused by a build-up of vasodilatory metabolites (Khanamiri et al. 2013) 
which may actually increase the degree of myocardial damage during reperfusion (Olivecrona et 
al. 2007).   
DHA treatment in this experiment did not reduce myocardial infarction area as measured by 
TTC staining.  This is in contrast to the previous observation in Sprague Dawley rats using a 
constant flow protocol, although is unclear if this is due to rat strain differences or the impact of 
constant flow vs. constant pressure protocols.  It may be possible that the effect of DHA 
treatment may not overcome the increased sensitivity of Wistar rats to ischemia-reperfusion 
injury (Javouhey et al. 1989), resulting in no observed differences in infarction.  In addition, the 
constant pressure protocol results in a different cardiac challenge.  Constant pressure, as opposed 
to constant flow perfusion, more closely approximates in vivo reperfusion, and a study 
employing constant pressure perfusion in ischemia-reperfusion models has shown no effect on 
infarction with n-3 HUFA feeding (Force et al. 1989).  The protective effect of DHA on 
infarction injury may then be partly dependent on a constant flow protocol, and thus was not 
observed in this study employing constant pressure perfusion.  In conclusion, in male Wistar rats 
there is evidence of preservation of myocardial function with DHA treatment, with increased left 
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ventricular rate of contraction and coronary flow in the reperfusion period.  However, in this 
model these changes were not associated with reductions in infarction as previously observed in 
Sprague-Dawley rats. 
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Table 4.  Effect of Gavage on Plasma Fatty Acid Weight Percent 
Fatty Acid Weight Percent (g/100g fatty acids) 
 Control DHA 
C 10:0 0.12 ± 0.07 0.12 ± 0.05 
C 12:0 0.04 ± 0.03 0.05 ± 0.03 
C 14:0 0.25 ± 0.04 0.28 ± 0.04 
C 16:0 18.76 ± 0.94 18.91 ± 0.77 
C 17:0 0.51 ± 0.05 0.51 ± 0.05 
C 18:0 15.17 ± 1.20 14.38 ± 1.56 
C 20:0 0.19 ± 0.04 0.16 ± 0.04 
C 22:0 0.38 ± 0.07 0.31 ± 0.06* 
C 23:0 0.29 ± 0.07 0.25 ± 0.06 
C 24:0 0.80 ± 0.15 0.74 ± 0.14 
Total SFA 36.85 ± 0.99 36.05 ± 1.45 
C 12:1 0.02 ± 0.01 0.03 ± 0.02 
C 14:1 0.03 ± 0.03 0.03 ± 0.03 
C 16:1 0.63 ± 0.19 0.65 ± 0.17 
C 18:1n-7 1.90 ± 0.22 1.82 ± 0.19 
C 18:1n-9 6.28 ± 0.89 7.08 ± 0.94 
C 20:1n-9 0.13 ± 0.02 0.12 ± 0.03 
C 22:1n-9 0.13 ± 0.07 0.14 ± 0.07 
C 24:1n-9 0.71 ± 0.09 0.69 ± 0.14 
Total MUFA 9.85 ± 0.98 10.58 ± 1.06 
C 18:2n-6 19.47 ± 1.32 20.51 ± 2.13 
C 18:3n-6 0.29 ± 0.06 0.26 ± 0.07 
C 20:2n-6 0.32 ± 0.06 0.28 ± 0.05 
C 20:3n-6 0.42 ± 0.09 0.46 ± 0.09 
C 20:4n-6 26.93 ± 1.59 24.65 ± 2.48* 
C 22:2n-6 0.14 ± 0.06 0.13 ± 0.03 
C 22:4n-6 0.34 ± 0.07 0.27 ± 0.05* 
C 22:5n-6 0.18 ± 0.08 0.19 ± 0.06 
Total n-6 PUFA 48.09 ± 1.23 46.76 ± 1.86 
C 18:3n-3 0.59 ± 0.11 0.62 ± 0.21 
C 20:3n-3 0.06 ± 0.03 0.06 ± 0.03 
C 20:5n-3 0.54 ± 0.11 0.82 ± 0.15* 
C 22:5n-3 0.57 ± 0.10 0.52 ± 0.08 
C 22:6n-3 2.10 ± 0.18 3.15 ± 0.34* 
Total N-3 PUFA 3.85 ± 0.31 5.17 ± 0.55* 
Total Fatty Acids 98.62 ± 0.26 98.56 ± 0.39 
Data is expressed as mean ± SD (n = 10 per group).  * indicates significantly different from 
controls (p < 0.05).  SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: 
polyunsaturated fatty acids. 
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Table 5.  Effect of Gavage on Plasma Total Fatty Acid Concentration 
Fatty Acid μg fatty acid/100 mL plasma 
 Control DHA 
C 10:0 0.12 ± 0.06 0.14 ± 0.07 
C 12:0 0.04 ± 0.03 0.05 ± 0.03 
C 14:0 0.27 ± 0.05 0.30 ± 0.09 
C 16:0 19.74 ± 3.21 20.70 ± 4.60 
C 17:0 0.53 ± 0.07 0.55 ± 0.09 
C 18:0 15.96 ± 2.75 15.76 ± 3.86 
C 20:0 0.19 ± 0.04 0.18 ± 0.04 
C 22:0 0.39 ± 0.05 0.33 ± 0.07* 
C 23:0 0.30 ± 0.06 0.27 ± 0.07 
C 24:0 0.83 ± 0.09 0.79 ± 0.13 
Total SFA 38.72 ± 5.61 39.44 ± 8.49 
C 12:1 0.02 ± 0.01 0.03 ± 0.02 
C 14:1 0.03 ± 0.03 0.04 ± 0.03 
C 16:1 0.66 ± 0.20 0.74 ± 0.41 
C 18:1n-7 2.01 ± 0.49 2.02 ± 0.63 
C 18:1n-9 6.63 ± 1.52 7.80 ± 2.31 
C 20:1n-9 0.13 ± 0.02 0.13 ± 0.03 
C 22:1n-9 0.13 ± 0.07 0.15 ± 0.08 
C 24:1n-9 0.74 ± 0.06 0.74 ± 0.13 
Total MUFA 10.38 ± 2.06 11.67 ± 3.36 
C 18:2n-6 20.48 ± 3.36 22.53 ± 5.86 
C 18:3n-6 0.31 ± 0.10 0.30 ± 0.16 
C 20:2n-6 0.33 ± 0.05 0.30 ± 0.09 
C 20:3n-6 0.44 ± 0.11 0.51 ± 0.18 
C 20:4n-6 28.50 ± 5.69 26.74 ± 4.85 
C 22:2n-6 0.14 ± 0.05 0.14 ± 0.03 
C 22:4n-6 0.35 ± 0.05 0.30 ± 0.09 
C 22:5n-6 0.19 ± 0.10 0.22 ± 0.09 
Total n-6 PUFA 50.73 ± 8.85 51.03 ± 10.36 
C 18:3n-3 0.62 ± 0.15 0.70 ± 0.37 
C 20:3n-3 0.06 ± 0.03 0.07 ± 0.04 
C 20:5n-3 0.58 ± 0.19 0.91 ± 0.33* 
C 22:5n-3 0.60 ± 0.14 0.58 ± 0.22 
C 22:6n-3 2.23 ± 0.53 3.49 ± 1.02* 
Total N-3 PUFA 4.08 ± 0.90 5.75 ± 1.85* 
Total Fatty Acids 103.91 ± 16.94 107.89 ± 23.55 
Data is expressed as mean ± SD (n = 10 per group) * indicates significantly different from 
controls (p < 0.05).  SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: 
polyunsaturated fatty acids. 
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Figure 17.  Left ventricular rate of contraction in male Wistar rats exposed to either a DHA or control soybean oil gavage 24 hours 
before experimentation.  * indicates significantly different (p<0.05) from control at that timepoint by unpaired t-test. Values are 
expressed as mean ± S.E.M. (n=5).  
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Figure 18.  Left ventricular developed pressure in male Wistar rats exposed to either a DHA or control soybean oil gavage 24 hours 
before experimentation.  Developed pressure is an index of the hearts ability to generate force and is calculated as the difference 
between systolic and diastolic pressure.  * indicates significantly different (p<0.05) from control at that timepoint by unpaired t-test. 
Values are expressed as mean ± S.E.M. (n=5).   
 
  
68 
 
0 2 0 4 0 6 0 8 0 1 0 0 1 2 0 1 4 0
0
5
1 0
1 5
2 0
2 5
T im e  ( M in u t e s )
C
o
r
o
n
a
r
y
 F
lo
w
 (
m
L
/m
in
)
C o n tr o l D H A
B a s e l in e
E n d  o f  I sc h e m ia
R e p e r f u s io n
*
*
*
C
o
n
tr
o
l
D
H
A
0
5 0 0
1 0 0 0
1 5 0 0
T r e a tm e n t  G r o u p
A
U
C
*
 
Figure 19.  Coronary flow in millilitres per minute in male Wistar rats exposed to either a DHA or control soybean oil gavage 24 
hours before experimentation.  * indicates significantly different (p<0.05) from control at that timepoint by unpaired t-test. Values are 
expressed as mean ± S.E.M. (n=5).   
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Figure 20.  Left ventricular end diastolic pressure in male Wistar rats exposed to either a DHA or control soybean oil gavage 24 hours 
before experimentation.  Diastolic pressure is an index of cardiac damage, with higher values being associated with increased 
myocardial damage following ischemia.  * indicates significantly different (p<0.05) from control at that timepoint by unpaired t-test. 
Values are expressed as mean ± S.E.M. (n=5).   
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Figure 21.  Left ventricular rate of relaxation in male Wistar rats exposed to either a DHA or control soybean oil gavage 24 hours 
before experimentation.  * indicates significantly different (p<0.05) from control at that timepoint by unpaired t-test. Values are 
expressed as mean ± S.E.M. (n=5).   
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Figure 22.  Left ventricular systolic pressure in male Wistar rats exposed to either a DHA or control soybean oil gavage 24 hours 
before experimentation.  * indicates significantly different (p<0.05) from control at that timepoint by unpaired t-test. Values are 
expressed as mean ± S.E.M. (n=5).   
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Figure 23.  Heart rate in beats per minute of male Wistar rats exposed to either a DHA or control soybean oil gavage 24 hours before 
experimentation.  * indicates significantly different (p<0.05) from control at that timepoint by unpaired t-test. Values are expressed as 
mean ± S.E.M. (n=5). 
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Figure 24.  The effect of acute DHA intake on infarcted area in male Wistar rats.  Data was 
analyzed by unpaired T-test.  Values are expressed as mean ± S.E.M. 
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Chapter 8 
Effect of a Single DHA intake on the Myocardial Lipid Profile and Enzymatic 
Antioxidant Content 
 
8.1. Introduction 
In response to acute DHA feeding, male Wistar rats demonstrated increased plasma EPA 
and DHA along with increased left ventricular and coronary vascular function following 
ischemia.  Previous feeding studies have implicated increased myocardial DHA (McGuinness et 
al. 2006) and enzymatic antioxidants (Castillo et al. 2013) in cardioprotection from ischemia-
reperfusion injury.  Therefore, these putative mechanisms that may explain the observed 
functional effect of acute DHA in male Wistar rats were investigated in a subset of animals.   
 
8.2. Study Protocols 
Standard chow fed male Wistar rats (3 – 5 months of age, n = 10) were gavaged with a 
single dose of DHA providing 0.4 mg DHA/g body weight or an equivalent volume of soybean 
oil as control.  Following gavage, rats were returned to their cages and had ad libitum access to 
food and water for 12h and were then fasted for an additional 12h.  Animals were then 
anaesthetized at 24 hours, and left ventricle tissue was collected. 
A portion of left ventricular tissue was immediately homogenized in a glass homogenizer 
with cold phenylmethylsulfonyl fluoride (PMSF), and frozen at -80°C for enzymatic antioxidant 
analysis by western blotting.  Total protein content was quantified by bicinchoninic acid assay.  
Samples containing 10 μg of protein were then separated in 10.5 - 12.5% polyacrylamide gels.  
Gels were then transferred to either nitrocellulose or polyvinyldifluoride (BioRad Laboratories, 
Mississauga, Canada) by semi-dry transfer.  Membranes were incubated overnight on a rocker at 
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4°C in 5% skim milk in 1x tris-buffered-saline with tween.  Membranes were incubated with 
primary antibodies in milk for MnSOD (ADI-SOD-110), CuZnSOD (SOD-100), and GPx (sc-
133160) according to supplier instructions for 1 hour.  After application of horseradish-
peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology), the enhanced 
chemiluminescence reagent ECL prime (GE Healthcare) was added to membranes.  Membranes 
were visualized with the ChemiGenius2 Bioimaging System (Syngene inc., Frederick MD) and 
densitometry analysis was performed using Genesnap software (version 7.07).  Molecular 
weights of proteins were identified using Precision Plus Protein WesternC Standards along with 
Precision Protein Strep-Tactin Horseradish Peroxidase Conjugated secondary antibody (Bio-Rad 
Laboratories).  Equal protein loading was confirmed following analysis of target proteins with 
ponceau S stain (Bioshop, Burlington ON, representative Ponceau stains are found in Appendix 
A).   
For fatty acid analysis, a portion of left ventricle was frozen at -80°C and pulverized in a 
mortar and pestle under liquid N2.  Pulverized samples were weighed and homogenized in 
chilled 2:1 chloroform methanol (v/v) containing 50 μg/ml butylated hydroxyl toluene (BHT) 
and docosatrienoic acid (C 22:3n-3) ethyl ester as an internal standard for absolute concentration 
determinations.  Subsequently, 500 μL of 0.2 M Na2PO4 buffer was added and samples were 
inverted and centrifuged at 1734 rcf for 5 minutes.  The organic phase was then collected and 
total lipid extracts were stored at -80°C until further analyses. 
Total lipid extracts were analysed by direct methylation for total lipid composition as 
described in section 4.4.  Additionally, left ventricular neutral lipids were separated into 
cholesteryl esters, non-esterified fatty acids, triacylglycerols, and total phospholipids by thin 
layer chromatography.  Total lipid extracts were applied to 20 x 20 cm plates with a 6nm silica 
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gel layer (Whatman Internation LTD, Maidstone, England) and separated with a mobile phase of 
heptane:diethyl ether:glacial acetic acid (60:40:2 v/v/v) (Christie 2003).  Bands were visualized 
under ultraviolet light using 2,7-dichloroflouorescein (Sigma-Aldrich, Oakville, ON, Canada) 
and were identified by comparison with reference standards.  Bands were then scraped, collected 
into tubes, and lipids were extracted from silica gel shavings with 2:1 choloroform:methanol 
(Folch et al. 1957) and methylated as described above.   
For lipidomic analysis to identify specific acyl species of lipids, pulverized tissue was 
independently weighed and homogenized in chilled 2:1 chloroform:methanol (v/v).  All samples 
were spiked with 3.33 nmol of 17:0/17:0 glycerophospohtidylcholine  and 3.33 nmol 17:0/17:0 
glycerophosphotidylethanolamine  dissolved in chloroform.  Samples were left in solvents 
overnight to increase lipid recovery.  A modified Folch double extraction was then performed as 
follows: after the addition of 500 μL 0.2 M Na2PO4 in water, samples were inverted and 
centrifuged at 1734 rcf for 5 minutes. The organic phase was collected and an additional 2 mL of 
chloroform were added to the aqueous layer left in the original test tube. Samples were vortexed 
for 1 minute and re-centrifuged at 1734 rcf for 5 minutes. The resulting organic layer was 
extracted and combined with the first.  Lipids were reconstituted in 100 μL 65:35:5 
acetonitrile:isopropanol:water (v/v/v) containing 0.1% formic acid.  Samples were run on a 
Dionex UPLC system coupled to a Thermo Scientific Q-Exactive Orbitrap-Quadrupole Hybrid 
Mass Spectrometer. A binary, multi-step gradient was used, consisting of (A) 60:40 
acetonitrile:water (v/v) and (B) 90:10 isopropanol:acetonitrile (v/v), both containing 10 mM 
ammonium formate and 0.1% formic acid.  The flow rate was set at 260 μL/min over a 47 
minute gradient protocol with a C18 Ascentis Express column (15 cm x 2.1 mm x 2.7 um).  The 
mass spectrometer was operated in positive electrospray ionization mode, with spray voltage of 
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3.0 kV, scan range of 200-2000 m/z, and under data-dependent acquisition conditions for the top 
5 ions in MS/MS.  MS/MS data was analyzed using the NIST 2.0 program, with the LipidBlast 
Database and the LipidMaps.org precursor ion search tool.  A targeted precursor ion list was 
created prior to running the samples for the [M+H]
+
 m/z values of all PC and PE 
glycerophospholipids containing DHA or EPA and even-chained fatty acids ranging from C 12:0 
to C 24:1.  Out of the 88 possible lipids that meet these criteria, 9 were confirmed in the samples 
(6 PC, 3 PE). There may be other glycerophospholipids containing EPA or DHA, however, due 
to factors such as ion suppression they were either not detectable or not verifiable by MS/MS.  
Ion profiles were extracted for the parent ions of the 9 lipids confirmed and the two lipid 
standards. Peaks were integrated and the area under the curve (AUC) for each peak was 
determined.  All values were normalized relative to the AUC of the equivalent lipid standard.   
 
8.3. Results 
There was no significant effect of DHA treatment on animal body or heart weight (p>0.05).  
Left ventricular total fatty acids were affected by a single high DHA gavage (Table 6), but to a 
lesser extent than the plasma pool.  The main myocardial lipid altered by DHA treatment was 
EPA, with concentrations increasing by 30% (p<0.05).  There was a trend towards increasing 
DHA in the left ventricle with DHA gavage, but this did not reach statistical significance 
(p=0.053) due to high inter-individual variability in this pool.  There were corresponding 
decreases in two saturated fatty acids, myristic (C 14:0) and lignoceric (C 24:0) acid. 
When individual lipid classes of the left ventricle were isolated, several fatty acids were 
found to be higher in the DHA group as compared with control.  Although DHA concentrations 
were elevated in both phospholipid (Table 7) and triacylglycerol (Table 8) pools, the former was 
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more significantly affected which is indicative of a preferential rapid incorporation of DHA into 
phospholipids over triacylglycerols.  In phospholipids, both EPA (p=0.024) and DHA (p=0.039), 
were significantly elevated relative to control treated animals.  Again, the increase in plasma 
eicosapentaenoic acid suggests DHA retro-conversion to EPA.  In the triacylglycerol pool (Table 
8), DHA (p=0.011), but not EPA (p>0.05), was elevated in DHA treated animals relative to 
control 24 hours following DHA feeding.  The increase in left ventricular phospholipid and 
triacylglycerol DHA was not associated with a corresponding decrease in n-6 PUFAs (p>0.05).  
The DHA oil also contains high levels of saturated fatty acids (composition detailed in Table 1) 
which appeared to affect the left ventricular fatty acid composition by increasing 22:0 in the 
phospholipid pool and both 12:0 and 14:0 in the triacylglycerol pool (p<0.05).   
There were no significant differences (p>0.05) in the concentration of either EPA or DHA in 
the phospholipid classes measured by lipidomic analysis (Table 9).  There were, however, 
significant trends towards increasing total DHA (p=0.081) and DHA in 
phosphatidylethanolamine (p=0.078) fractions, primarily driven by increases in 16:0, 22:6n-3 
PE.  DHA concentrations were much greater in the phosphatidylethanolamine fraction than 
phosphatidylcholine.  EPA concentrations, while observable in the phosphatidylcholine fraction, 
were minimal in phosphatidylethanolamine and therefore could not be quantified.  Although 
increases in EPA and DHA were observed in total left ventricular phospholipids, lipidomic 
analysis did not implicate the myocardial phosphatidylcholine or phosphatidylethanolamine 
pools in this effect. 
The myocardial protein content of the enzymatic antioxidants assayed, namely MnSOD, 
CuZnSOD, and GPx, was not significantly elevated 24 hours following a single DHA intake in 
male Wistar rats (p>0.05, Figure 25).  
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8.4. Discussion 
A single DHA feeding resulted in increased myocardial DHA accretion in both the 
phospholipid and triacylglycerol pools, but not when measured in total lipid extract.  
Incorporation of EPA and DHA into the myocardial membrane has been implicated in 
cardioprotection (McGuinness et al. 2006) and may act through one or a combination of several 
pathways including alterations of membrane structure and function, lipid mediators of 
inflammation, and oxidative stress and upregulation of enzymatic antioxidants (discussed in 
Chapter 7).   
Enzymatic antioxidants protect the heart from the damaging effect of ROS, including 
impairment of left ventricular function and induction of apoptotic cell death (Jones et al. 2003).  
This data did not support the hypothesis that DHA enhanced cardioprotection through the 
upregulation of enzymatic antioxidants, as the protein content of CuZnSOD, MnSOD, and GPx 
were not increased 24 hours after a single DHA feeding.  It may be that longer term DHA 
treatment may be required to increase enzymatic antioxidant content.  It has been demonstrated 
in chronic feeding studies ranging from 4 (Jahangiri et al. 2006) to 8 weeks in length (Castillo et 
al. 2013).    It is also possible that, due to the time lag between digestion and incorporation into 
the myocardial membrane, 24 hours may not have provided enough time for the detection of 
increased enzymatic antioxidants.  Following a preconditioning stimulus, the enzymatic 
antioxidant MnSOD was shown to rise slowly and did not peak until after 24 hours (Hoshida et 
al. 1993).  Although no data is available on the time between a single DHA intake and 
myocardial incorporation, human studies have shown that n-3 HUFA does not peak in plasma 
until between 4 (Hanwell et al. 2009) and 6 (Harris et al. 2013) hours after ingestion.  Therefore, 
any stimulus from DHA-induced oxidative stress may have not affected myocardial enzymatic 
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antioxidants until at least 4 to 6 hours after ingestion and an increase may not have been 
detectable until 24 hours after this stimulus.  Additionally, the specific antioxidants measured 
may have affected whether or not an effect was observed.  MnSOD has been implicated as a key 
contributor to the late phase of preconditioning and, as mentioned, it does not peak until 24 hours 
following the preconditioning stimulus (Hoshida et al. 1993).  GPx, CAT, and MnSOD have 
been shown to increase following chronic dietary intervention (Jahangiri et al. 2006), although 
the time for this adaptation to occur is not known.  HO-1 has been implicated in cardioprotection 
in several studies, and is related to 4-HXE levels through Nrf2 signalling (Nakagawa et al. 2014; 
Ishikado et al. 2013), but was not assayed in this study.  It is possible that at 24 hours another 
assessment of upregulation of enzymatic antioxidants such as the nuclear translocation of Nrf2 or 
the mRNA of enzymatic antioxidants assayed by RT-PCR may have detected the early phases of 
upregulation.  It is equally possible that at a later timepoint increases in enzymatic antioxidants 
may have been detectable.  The lack of an increase in these enzyme antioxidants could possibly 
explain the lack of an effect of DHA treatment on infarction in male Wistar rats. 
In conclusion, acute DHA feeding increases myocardial DHA accretion, particularly in the 
phospholipid and triacylglycerol pools.  DHA does not increase the protein content of the 
enzymatic antioxidants CuZnSOD, MnSOD, and GPx and they are therefore not implicated in 
the effects on left ventricular function observed in this model.  However, lacking a more 
comprehensive review of enzymatic antioxidant expression, it is impossible to state that their 
upregulation was not involved.  Further assessment of other enzymatic antioxidants and different 
timepoints should be undertaken to determine if acute DHA feeding increases enzymatic 
antioxidants and was not detected in this particular model.   
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Table 6.  Effect of Gavage on Left Ventricular Total Lipid Fatty Acid Concentration 
Fatty Acid μg fatty acid/100 mg tissue 
 Control DHA 
C 10:0 nd nd 
C 12:0 0.2 ± 0.1 0.2 ± 0.0 
C 14:0 5.1 ± 0.5 4.1 ± 0.4* 
C 16:0 110.3 ± 3.6 107.0 ± 3.5 
C 17:0 0.9 ± 0.1 0.9 ± 0.1 
C 18:0 201.3 ± 11.6 196.2 ± 10.8 
C 20:0 1.8 ± 0.3 1.7 ± 0.2 
C 22:0 1.5 ± 0.2 1.5 ± 0.2 
C 23:0 0.7 ± 0.0 0.6 ± 0.0 
C 24:0 1.1 ± 0.4 0.3 ± 0.0* 
Total SFA 329.6 ± 15.9 319.9 ± 13.4 
C 12:1 nd nd 
C 14:1 nd nd 
C 16:1 1.2 ± 0.2 1.3 ± 0.2 
C 18:1n-7 28.0 ± 1.3 26.7 ± 2.2 
C 18:1n-9 29.9 ± 3.8 30.1 ± 7.0 
C 20:1n-9 0.7 ± 0.1 0.7 ± 0.1 
C 22:1n-9 0.5 ± 0.2 0.7 ± 0.1 
C 24:1n-9 0.3 ± 0.1 0.3 ± 0.1 
Total MUFA 64.4 ± 3.3 64.5 ± 8 
C 18:2n-6 198.2 ± 31.0 189.3 ± 26.5 
C 18:3n-6 1.2 ± 0.1 1.1 ± 0.1 
C 20:2n-6 2.9 ± 0.2 2.5 ± 0.2 
C 20:3n-6 3.3 ± 0.7 2.9 ± 0.3 
C 20:4n-6 176.8 ± 13.9 172.2 ± 15.3 
C 22:2n-6 0.2 ± 0.1 0.2 ± 0.1 
C 22:4n-6 9.5 ± 1.5 8.9 ± 1.1 
C 22:5n-6 6.2 ± 2.2 6.0 ± 1.3 
Total n-6 PUFA 398.3 ± 41.3 383.2 ± 39.2 
C 18:3n-3 2.1 ± 0.3 1.8 ± 0.2 
C 20:3n-3 0.2 ± 0.1 0.2 ± 0.1 
C 20:5n-3 1.0 ± 0.1 1.3 ± 0.1* 
C 22:5n-3 27.8 ± 2.3 25.0 ± 1.9 
C 22:6n-3 110.7 ± 8.7 125.4 ± 11.5
(p=0.053)
 
Total N-3 PUFA 141.8 ± 8.0 153.7 ± 12.3 
Total Fatty Acids 934.0 ± 54.3 921.4 ± 50.4 
Data is expressed as mean ± SD (n = 5 per group) * indicates significantly different from 
controls (p < 0.05) by independent t-test.  SFA: saturated fatty acids, MUFA: monounsaturated 
fatty acids, PUFA: polyunsaturated fatty acids, nd: not detected. 
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Table 7.  Effect of Gavage on Left Ventricular Phospholipid Fatty Acid Concentration 
Fatty Acid μg fatty acid/100 mg tissue 
 Control DHA 
C 10:0 0.2 ± 0.1 nd 
C 12:0 1.4 ± 0.3 1.6 ± 0.2 
C 14:0 5.4 ± 1.1 7.7 ± 0.4 
C 16:0 129.8 ± 5.7 146.9 ± 8 
C 18:0 271.7 ± 12.5 291.7 ± 17 
C 20:0 2.9 ± 0.1 3.0 ± 0.1 
C 22:0 2.1 ± 0.2 2.8 ± 0.1* 
C 24:0 0.6 ± 0.1 0.8 ± 0.2 
Total SFA 414.0 ± 17.6 454.6 ± 24.8 
C 12:1 0.7 ± 0.2 1.3 ± 0.2 
C 14:1 0.1 ± 0.1 0.6 ± 0.5 
C 16:1 2.6 ± 0.1 4.0 ± 0.1* 
C 18:1n-7 32.9 ± 1.1 34.0 ± 2.6 
C 18:1n-9 32.4 ± 4.0 32.7 ± 2.3 
C 20:1n-9 1.6 ± 0.2 1.4 ± 0.1 
C 22:1n-9 0.9 ± 0.1 1.1 ± 0.1 
C 24:1n-9 0.3 ± 0.1 0.3 ± 0.1 
Total MUFA 71.4 ± 5.0 75.3 ± 5.1 
C 18:2n-6 223.8 ± 20.5 243.1 ± 15.5 
C 18:3n-6 0.3 ± 0.1 0.3 ± 0.1 
C 20:2n-6 2.9 ± 0.1 2.8 ± 0.2 
C 20:3n-6 3.0 ± 0.2 3.1 ± 0.2 
C 20:4n-6 188.6 ± 10.9 200.6 ± 16.4 
C 22:2n-6 0.2 ± 0.1 0.3 ± 0.1 
C 22:4n-6 9.0 ± 0.8 9.1 ± 0.5 
C 22:5n-6 5.7 ± 0.9 6.2 ± 0.8 
Total n-6 PUFA 433.4 ± 31.2 465.4 ± 31.2 
C 18:3n-3 1.5 ± 0.1 1.6 ± 0.1 
C 20:3n-3 0.5 ± 0.1 0.5 ± 0.0 
C 20:5n-3 0.9 ± 0.1 1.2 ± 0.1* 
C 22:5n-3 25.1 ± 1.9 25.6 ± 2.7 
C 22:6n-3 106.6 ± 3.4 130.2 ± 9.0* 
Total N-3 PUFA 134.6 ± 4.5 159.0 ± 11.7 
Total Fatty Acids 1053.4 ± 54.0 1154.4 ± 65.8 
Data is expressed as mean ± SD (n = 5 per group) * indicates significantly different from 
controls (p < 0.05) by independent t-test.  SFA: saturated fatty acids, MUFA: monounsaturated 
fatty acids, PUFA: polyunsaturated fatty acids, nd: not detected. 
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Table 8.  Effect of Gavage on Left Ventricular Triacylglycerol Fatty Acid Concentration 
Fatty Acid μg fatty acid/100 mg tissue 
 Control DHA 
C 10:0 0.1 ± 0.1 0.1 ± 0.1 
C 12:0 0.4 ± 0.1 1.0 ± 0.2* 
C 14:0 1.9 ± 0.2 3.0 ± 0.4* 
C 16:0 34.1 ± 1.9 39.4 ± 3.8 
C 18:0 21.5 ± 0.5 24.7 ± 2.2 
C 20:0 0.9 ± 0.1 1.1 ± 0.1 
C 22:0 0.7 ± 0.1 0.9 ± 0.1 
C 24:0 0.1 ± 0.0 0.4 ± 0.1 
Total SFA 59.7 ± 2.4 70.6 ± 5.7 
C 12:1 0.1 ± 0.1 0.1 ± 0.1 
C 14:1 0.1 ± 0.1 0.1 ± 0.1 
C 16:1 3.6 ± 0.3 4.3 ± 0.2 
C 18:1n-7 3.9 ± 0.3 4.5 ± 0.5 
C 18:1n-9 16.2 ± 1.8 19.2 ± 3.3 
C 20:1n-9 0.4 ± 0.1 0.3 ± 0.0 
C 22:1n-9 0.7 ± 0.1 1.0 ± 0.1 
C 24:1n-9 0.1 ± 0.1 0.1 ± 0.1 
Total MUFA 25.1 ± 2.4 29.5 ± 3.7 
C 18:2n-6 24.3 ± 2.8 24.9 ± 5.5 
C 18:3n-6 0.3 ± 0.1 0.2 ± 0.1 
C 20:2n-6 0.5 ± 0.1 0.4 ± 0.1 
C 20:3n-6 0.5 ± 0.1 0.4 ± 0.1 
C 20:4n-6 3.9 ± 0.2 4.0 ± 0.3 
C 22:2n-6 0.3 ± 0.1 0.3 ± 0.1 
C 22:4n-6 0.9 ± 0.1 0.8 ± 0.1 
C 22:5n-6 0.2 ± 0.1 1.9 ± 1.5 
Total n-6 PUFA 30.9 ± 3.3 32.9 ± 6.1 
C 18:3n-3 0.7 ± 0.1 0.7 ± 0.2 
C 20:3n-3 0.5 ± 0.1 0.6 ± 0.0 
C 20:5n-3 0.3 ± 0.1 0.4 ± 0.1 
C 22:5n-3 1.5 ± 0.2 1.4 ± 0.1 
C 22:6n-3 2.4 ± 0.3 3.9 ± 0.3* 
Total N-3 PUFA 5.3 ± 0.6 7.0 ± 0.5 
Total Fatty Acids 121.0 ± 8.3 140.0 ± 14.6 
Data is expressed as mean ± SD (n = 5 per group) * indicates significantly different from 
controls (p < 0.05) by independent t-test.  SFA: saturated fatty acids, MUFA: monounsaturated 
fatty acids, PUFA: polyunsaturated fatty acids, nd: not detected. 
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Table 9.  Effect of Gavage on n-3 HUFA in Left Ventricular Phospholipid Acyl-Species 
Phospholipid Class Sn-1 Acyl Sn-2 Acyl Concentration (nmol/100 mg) 
   Control DHA 
Phosphotidylcholine 16:0  20:5n-3 3.4 ± 0.5 3.0 ± 0.1 
 18:0 20:5n-3 4.0 ± 0.7 3.8 ± 0.3 
 Sum 20:5n-3 PC          7.4 ± 1.2 6.8 ± 0.4 
     
 16:0 22:6n-3 39.6 ± 3.3 61.1 ± 10.1 
 18:0 22:6n-3 61.9 ± 5.0 72.4 ± 10.8 
 18:1 22:6n-3 1.8 ± 0.1 3.0 ± 0.6 
 18:2 22:6n-3 7.3 ± 1.0 10.9 ± 1.7 
 Sum 22:6n-3 PC 110.6 ± 7.4 147.4 ± 23.1 
     
Phosphotidylethanolamine 16:0 22:6n-3 230.1 ± 20.7 315.8 ± 37.5 
 18:1 22:6n-3 45.0 ± 3.8 58.9 ± 5.9 
 18:2 22:6n-3 34.5 ± 3.1 49.0 ± 7.4 
 Sum 22:6n-3 PE 309.6 ± 26.2 423.7 ± 50.1 
Data is expressed as mean ± SEM (n = 5 per group).  Data was analysed by independent t-test.  
PC: phosphotidylcholine; PE: phosphotidylethanolamine.  
 
 
 
 
Figure 25.  The effect of DHA treatment on the protein content of enzymatic antioxidants in the 
left ventricle (A).  Values are expressed as mean ± S.E.M. (n=5).  Representative blots of 
MnSOD, CuZnSOD, and GPx are shown in figures B, C, and D, respectively.   
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Chapter 9 
Discussion 
 
 DHA has been implicated in cardioprotection in both epidemiological studies (Albert et 
al. 2002) and laboratory investigations in animals (Zeghichi-Hamri et al. 2010), and one of the 
cardioprotective mechanisms appears to involve the reduction of ischemia-reperfusion injury 
(Castillo et al. 2013; Zeghichi-Hamri et al. 2010).  Ischemia-reperfusion injury results in 
myocardial functional impairment and infarction, which is caused in large part by ROS (Kim et 
al. 2006; Temsah et al. 1999) but can be alleviated with antioxidant enzymes (Das et al. 1992; 
Jones et al. 2003).  Chronic dietary intervention with EPA and DHA increases cellular 
antioxidant enzymes (Jahangiri et al. 2006) and affords protection from ischemia-reperfusion 
injury (Castillo et al. 2013), possibly through detoxification of ROS.  Counterintuitively, EPA 
and DHA feeding increases oxidative stress (Vossen et al. 1995), and DHA and is susceptible to 
lipid peroxidation (Saito & Kubo 2003).  However, products of peroxidation increase the 
expression and protein content of enzymatic antioxidants, and this adaptation can occur in less 
than 24 hours (Zhang et al. 2010).  The ability of DHA to effect changes in myocardial 
susceptibility to ischemia reperfusion injury in this time frame has not been characterized.  
Therefore this thesis evaluated the effect of acute DHA intake on susceptibility to ischemia-
reperfusion injury, myocardial DHA accretion, and enzymatic antioxidant content.   
A single dose of DHA affected left ventricular function at 24 hours in both strains and 
perfusion methods studied, although the effect of DHA differed between the two models.  DHA 
feeding lowered baseline left ventricular function in male Sprague Dawley rats perfused at 
constant flow, but did not cause comparable baseline impairment in male Wistar rats perfused at 
  
86 
 
constant pressure.  Sprague-Dawley rats demonstrated reduced left ventricular function in the 
reperfusion period, but increased recovery relative to baseline levels.  Wistar rats exhibited some 
degree of improved left ventricular function following ischemia-reperfusion injury, but not the 
same extent as Sprague-Dawley male rats.  There were no differences in the coronary perfusion 
pressure in male Sprague-Dawley rats, while male Wistar rats had higher coronary flow 
following ischemia with acute DHA feeding.   The literature surrounding the effect of EPA and 
DHA treatment on left ventricular functional recovery following ischemia-reperfusion injury is 
mixed, with some studies having found improved recovery from myocardial ischemia-
reperfusion (Castillo et al. 2013; Abdukeyum et al. 2008) and others detecting no difference in 
recovery (Force et al. 1989; Zeghichi-Hamri et al. 2010; McGuinness et al. 2006).  Myocardial 
infarction, as measured by TTC staining, also was strain-dependent.  A single DHA feeding 
reduced infarction in Sprague-Dawley rats independent of sex.  Conversely, there was no effect 
of DHA on infarction in male Wistar rats.  Evidence in the literature is again mixed as to the role 
of DHA in reducing myocardial infarction, with some studies describing a reduction in 
myocardial infarction (Castillo et al. 2013; Zeghichi-Hamri et al. 2010) while others have 
reported no effect (Force et al. 1989).    
The coronary flow response may also explain the different results observed in the two DHA 
treatment models.  In constant pressure perfusion, there was an approximately 30% increase in 
flow relative to baseline observed immediately following ischemia independent of treatment 
group, a phenomenon termed reactive hyperemia (Khanamiri et al. 2013).  In providing increased 
flow, the small effect previously observed with DHA treatment on infarction in constant flow 
studies may have been masked, as reactive hyperemia may actually increase the degree of 
myocardial damage during reperfusion (Olivecrona et al. 2007).   In constant flow perfusion, 
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reactive hyperemia does not occur, and could potentially explain the observation of an effect of 
DHA on myocardial infarction in this model.   
The female response to DHA treatment differed markedly from males.  Female hearts of 
Sprague-Dawley rats did not demonstrate increased recovery of any left ventricular functional 
parameters with DHA treatment.  Baseline left ventricular functional differences with treatment, 
which were apparent in males, also did not occur in female hearts.  Therefore acute DHA intake 
did not affect the left ventricular function of female hearts, and did not result in increased 
protection from ischemia-reperfusion injury.  One possible explanation is that DHA-mediated 
alterations in left ventricular function may not have any effect in females due to their innately 
higher myocardial DHA content (Kitson et al. 2012).  Females also have increased 
phosphorylation and activity of the antioxidant enzyme aldehyde dehydrogenase (ALDH2) 
(Lagranha et al. 2010) along with increased myocardial n-3 HUFA content, which has been 
shown to increase cellular oxidative stress defence through the upregulation of enzymatic 
antioxidants (Jahangiri et al. 2006; Castillo et al. 2013).   
Acute DHA intake resulted in altered myocardial and plasma lipid profiles after 24 hours. 
Previous human studies have demonstrated plasma level increases 24 hours following a single n-
3 HUFA intake (Yang et al. 2012), but in the animal ischemia-reperfusion injury literature 
chronic dietary interventions are typically used and this is the first study to demonstrate 
myocardial EPA and DHA accretion 24 hours following a single DHA feeding.  It was 
hypothesized that in this acute time frame DHA would increase principally in plasma, and thus 
any effects on the cardiovascular system would be mediated by free DHA and not membrane 
DHA.  Only total fatty acids were analyzed in the plasma pool and therefore conclusions cannot 
be drawn as to the molecular form of DHA within plasma.  However, inferences can be made 
  
88 
 
from human studies, which have demonstrated DHA increases peak in the plasma phospholipid 
pool at 24 hours (Raatz et al. 2009) while red blood cell incorporation is comparatively delayed 
(Metherel et al. 2009). 
The effect of acute DHA intake on myocardial lipids was not immediately evident, as the 
DHA concentration was not significantly elevated in myocardium total lipids after 24 hours 
(Table 6).  However, DHA was found to be elevated in both the phospholipid (Table 7) and 
triacylglycerol (Table 8) pools.  DHA is preferentially incorporated into phospholipids, and 
particularly PE (Kubo et al. 2000).  An increase in triacylglycerol DHA is interesting as this is 
not typically thought to be a site of DHA accumulation.  Previous studies have demonstrated 
myocardial DHA accretion following more prolonged n-3 HUFA intake of between 4 (Jahangiri 
et al. 2006) and 8 weeks (Castillo et al. 2013).   
As the DHA source used contained trace amounts of EPA (Table 3) it was hypothesized that 
there would be minimal EPA accumulation in plasma and left ventricle.  However, EPA 
concentrations in plasma and myocardial lipids increased significantly, suggesting that the DHA 
provided was retroconverted to EPA.  This is the first observation of increased absolute EPA 
concentrations in the heart lipid pools after a single oral dose of DHA.  DHA conversion to EPA 
has been observed in longer term human supplementation studies (Stark & Holub 2004) and 
radioisotope tracer studies examining plasma have indicated that DHA retroconversion to EPA 
can occur after a single dose of DHA in both rats and humans (Brossard et al. 1996).  It is 
believed that this occurs through β-oxidation in the peroxisome (Stark & Holub 2004).  
Therefore the response to DHA feeding may include effects of EPA on cardiovascular function.  
EPA is a precursor to eicosanoids and competes directly with ARA for phospholipid 
incorporation.  EPA is a precursor to anti-inflammatory lipid mediators (Ohnishi & Saito 2013), 
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and has demonstrated anti-inflammatory properties in cardiovascular disease (Cawood et al. 
2010).  Because of retroconversion, separating the specific effects of EPA and DHA through 
dietary treatment may be very difficult and it therefore may be necessary to directly infuse DHA 
into the heart to examine the individual effects of EPA and DHA. 
The protein content of the enzymatic antioxidants MnSOD, CuZnSOD, and GPx was not 
significantly altered 24 hours following DHA treatment, indicating that these particular 
antioxidant enzymes are not implicated in the observed effects on left ventricular and coronary 
vascular function observed in this model.  However, lacking a more comprehensive review of 
enzymatic antioxidant expression including assessment in Sprague-Dawley rats, it is impossible 
to state that their upregulation was not involved.  Unfortunately, these enzymes were not 
measured in the constant flow model where an infarction effect was observed.  Other studies, 
employing longer term EPA and DHA supplementation protocols, have demonstrated increased 
expression and/or protein content of enzymatic antioxidants in murine models (Jahangiri et al. 
2006; Castillo et al. 2013).   
Although it was hypothesized that DHA increased oxidative stress following acute intake and 
would result in increased expression of enzymatic antioxidants, oxidative stress and all potential 
enzymatic antioxidants were not assayed in these studies.  However, previous studies have 
demonstrated that chronic dietary intervention with n-3 HUFA results in increased oxidative 
stress in several models studied including endothelial cells (Vossen et al. 1995), plasma (Song et 
al. 2000), liver (Farina et al. 2003), kidney (Ibrahim et al. 1999), and human blood biomarkers 
(Garcia-Alonso et al. 2012).  Increased oxidative stress is detrimental to cardiovascular function, 
and this effect is partially mediated by reactive aldehydes, which are a product of fatty acid 
peroxidation.  4-hydroxy-2-nonenal (4-HNE) is a product of the non-enzymatic oxidation of 
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ARA, and it has been shown to cause cell death at concentrations >10μM in isolated 
cardiomyocytes (Zhang et al. 2010).  However, these products may also be cardioprotective, as 
they are ligands for transcription factors including Nrf2 which controls downstream expression 
of several genes related to oxidative stress and the inflammatory response (Zhang et al. 2010; 
Ishikado et al. 2013).  The n-3 derived lipid peroxidation product, 4-hydroxyhexenal has been 
shown to increase the enzymatic antioxidants catalase, GSTA1, and GCLC (Anderson et al. 
2012) and HO-1 (Nakagawa et al. 2014) in the murine heart.   
As there were no appreciable adaptations in the antioxidant system detected in these studies, 
myocardial EPA and DHA accretion may be acting through another mechanism in order to cause 
changes in left ventricular and coronary vascular function.  This may include alterations in 
membrane structure and function, as incorporation of n-3 HUFA into myocardial phospholipids 
affects the function of numerous signal transduction pathways originating at the membrane.  
Inhibition of toll-like receptor 4 (TLR4), a receptor mediator of the inflammatory response in the 
plasma membrane, by EPA and DHA has significant downstream effects including the inhibition 
of lipopolysaccharide-induced inflammation, COX-2 expression, and NFκB activation (Lee et al. 
2003).  This has been attributed to the ability of DHA to inhibit the lipid-raft dependent 
dimerization and recruitment of TLR4, which is a critical step in the signalling pathway (Wong 
et al. 2009).  Another inflammatory signalling pathway, PKCθ, was found to be inhibited in 
animals fed diets enriched in either fish oil or DHA alone resulting in inhibition of downstream 
inflammatory responses including NFκB activation and interleukin-2 secretion (Fan et al. 2004).  
It is thought that DHA incorporation into plasma membrane phophotidylcholine and 
phosphatidylethanolamine and a corresponding reduction in lipid raft sphingomyelin was 
responsible for disruption of this signalling pathway. 
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Observed effects may also be attributable to DHA-derived lipid mediators, as DHA in 
myocardial phospholipids serves as a precursor to resolvins and protectins which may have roles 
in cardioprotection.  Resolvin D1 has been shown to activate inflammation resolution following 
myocardial infarction, resulting in improved ventricular function (Kain et al. 2015).  DHA 
displaces ARA in the myocardial membrane, and this may reduce some of the proinflammatory 
effects of ARA and its derivatives, which has been shown to promote inflammation and cause 
left ventricular dysfunction following a myocardial infarction (Kain et al. 2014).       
Myocardial DHA may also affect hemodynamic function through ion channel modulation.  
During ischemia, the activity of plasmalogen-specific phospholipase A2 is increased (Ford et al. 
1991), resulting in cleavage of fatty acyls including n-3 HUFA from the sn-2 position of plasma 
membrane phospholipids.  This pool of liberated n-3 HUFA could potentially exert anti-
arrhythmic effects through direct effects on myocardial ion channels including the voltage gated 
L-type Ca
2+
 channel (Xiao et al. 1997) and the alpha subunit of the sodium channel (Xiao et al. 
2001).  Isolated heart studies have demonstrated myocardial protection from ischemia-
reperfusion injury with infusion of n-3 HUFA directly into the perfusate likely demonstrating an 
effect of DHA in the free fatty acid pool (Smith et al. 2012; Richard et al. 2014).   
 
9.1. Limitations and Future Directions 
Issues with the models used in these studies may limit the interpretation of findings and their 
applicability to human clinical populations.  However, further study can be undertaken in order 
to increase understanding of the mechanistic role of acute DHA intake in the findings of these 
studies.  It will be important to fully characterize the biochemical and molecular pathways that 
pertain to the observed reductions in left ventricular function, improved post-ischemic contractile 
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recovery, and elevated reperfusion coronary flow, as well as the evident strain and perfusion 
differences.     
  The Langendorff isolated heart model is an excellent model for mechanistic study of the 
heart, in that it facilitates the isolation of the myocardium from neural and hormonal 
confounders.  By utilizing constant pressure perfusion, the physiological relevance is increased 
as the flow rate is regulated by the coronary vasculature as it is in vivo.  However, the isolated 
heart is still a non-physiological model, and application to in vivo situations may be limited.  The 
rat is a common model used for cardiovascular study, although differences between the cardiac 
function in humans and rats may limit application of some findings.  Of note, the Ca
2+
 
sequestration during diastole differs significantly between humans and rats, with rats relying 
more heavily on SERCA activity than humans (Bers 2002).  Additionally, the dose of DHA used 
may not be clinically applicable.  Although equivalent high doses of n-3 HUFA have been used 
in both murine models (Zeghichi-Hamri et al. 2010) and human studies (Endres et al. 1989), such 
a high dose may not be feasible in human populations due to both tolerance of adverse side-
effects and cost.     
Studying the effect of acute DHA treatment using both heart perfusion techniques and 2 
animal strains provided insight into its effect on the cardiovascular system.  However, as these 
factors were not studied independently but were rather changed simultaneously for reasons of 
physiological relevance and increased ischemic susceptibility, it is difficult to definitively 
discuss the independent effect of either rat strain or perfusion method on ischemia-reperfusion 
injury.  Assays that were performed in Wistar rats, namely myocardial DHA accretion and 
enzymatic antioxidants, were not performed in Sprague-Dawley rats and again make comparison 
between the 2 strains difficult.  Therefore, strain differences in the molecular targets of 
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preconditioning should be characterized more fully, as they may contribute to the differential 
response in Sprague-Dawley and Wistar rats.  These include differences in enzymatic 
antioxidants and myocardial DHA accretion.     
EPA and DHA are often studied in combination in animal and human studies, which 
complicates interpretation of experimental results as it is unclear whether the fatty acids act 
individually or in combination.  DHA was used for investigations in this thesis due to its 
increased susceptibility to peroxidation relative to EPA, as it was hypothesized that the n-3 
HUFA would act through oxidative stress pathways to reduce ischemia-reperfusion injury.  It is 
unknown at this point what effect EPA or EPA + DHA treatment would have on ischemia-
reperfusion injury 24 hours later.  Although insights gained from this work indicate a potential 
effect of acute DHA feeding on cardiovascular function, application to human populations may 
be limited as EPA and DHA are often found together in whole foods and nutraceuticals.   The n-
3 HUFA EPA, although less susceptible to peroxidation than DHA, may still elicit a similar 
myocardial response following acute intake.  In fact, these results suggest that increased EPA in 
the myocardium with DHA treatment may actually be contributing to cardioprotection from 
ischemia-reperfusion injury in this model.  Therefore the effect of EPA individually and in 
combination with DHA should be tested.   
Although enzymatic antioxidants were assayed in this study, other known physiological 
effects of DHA on the cardiovascular system including, but not limited to, ion channel kinetics, 
membrane structure and function, and lipid mediator effects were not measured.  Therefore, their 
role in these observations should be investigated further.  It is also not clear at this time if the 
dose used in these studies caused an increase in myocardial oxidative stress, and if this signal 
acted through traditional preconditioning pathways such as the ROS-sensitive transcription factor 
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Nrf2.  This could explain the lack of an effect on enzymatic antioxidant content, and therefore 
the oxidative stress in the myocardium following DHA intake should be characterized, including 
the role of lipid peroxidation and the formation of the reactive aldehyde 4-HXE.  The extent of 
Nrf2 pathway activation in response to oxidative stress, as well as the expression and content of 
its downstream antioxidant targets, including GSTA1 and GCLC, should also be characterized.   
 
9.2. Conclusions 
These results demonstrate that a single oral dose of DHA affects the function of the isolated 
rat heart just 24 hours following intake.  At baseline, DHA resulted in reduced left ventricular 
contractility in male Sprague-Dawley rats, although this effect was dependent on both animal sex 
and strain, as female heart function and the baseline function of hearts from Wistar rats were not 
affected by DHA treatment.  DHA intake also affected the myocardial response to ischemia-
reperfusion injury, as male Sprague-Dawley and Wistar rats demonstrated improved recovery of 
left ventricular function during reperfusion, with DHA-treated Wistar rats also demonstrating 
increased reperfusion coronary flow.   These functional changes are associated with an altered 
plasma total lipid and left ventricular phospholipid profile, with significant increases in both the 
n-3 HUFA EPA and DHA and, in the case of plasma total lipid, a corresponding decrease in the 
relative percent of the n-6 HUFA ARA.  Although oxidative stress pathways may alter the 
enzymatic antioxidant content of the myocardium resulting in cardioprotection, there was no 
evidence for the involvement of MnSOD, CuZnSOD, or GPx in this model as protein levels of 
these enzymes were not increased 24 hours following DHA treatment.  Taken together, these 
results suggest that acute DHA intake modulates the baseline left ventricular function, coronary 
vascular tone, and ischemic susceptibility of the myocardium 24 hours later, but these effects are 
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dependent on strain, sex, and perfusion method.  These alterations were associated with 
myocardial EPA and DHA accretion, particularly in myocardial phospholipids, but not an 
increased content of the enzymatic antioxidants assayed.  
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Appendix 
 
Figure 26.  Representative Ponceau S stain demonstrating equal protein loading of 
polyvinyldifluoride membrane used for chemiluminescent analysis of CuZnSOD protein levels 
in hearts from male Wistar rats.    
 
Figure 27.  Representative Ponceau S stain demonstrating equal protein loading of 
polyvinyldifluoride membrane used for chemiluminescent analysis of MnSOD protein levels in 
hearts from male Wistar rats.   
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Figure 28.  Representative Ponceau S stain demonstrating equal protein loading of 
polyvinyldifluoride membrane used for chemiluminescent analysis of GPx protein levels in 
hearts from male Wistar rats.   
  
